Loading...
Loading...
Evidence-based scoring tools, formulas, and dosing calculators for clinical decision support.
Diagnostic criteria for infective endocarditis combining major (blood culture, echocardiographic) and minor (predisposing conditions, fever, vascular phenomena) criteria.
Estimates creatinine clearance (CrCl) as a proxy for GFR. Widely used for drug dosing adjustments in renal impairment.
Standardized assessment of consciousness level based on eye opening, verbal response, and motor response. Used to monitor neurological status and guide management.
Predicts 6-week risk of major adverse cardiac events (MACE) in patients presenting to the emergency department with chest pain.
Calculates BMI from weight and height. Used to classify weight status and estimate obesity-related health risk.
Calculates weight-based N-Acetylcysteine (NAC) dosing for acetaminophen overdose treatment. Supports both IV and oral protocols.
Identifies children at very low risk for clinically-important traumatic brain injury (ciTBI) after blunt head trauma, guiding CT scan utilization.
Quantifies the pre-test probability of pulmonary embolism (PE) to determine the necessity of D-dimer vs. CT angiography.
Estimates the pre-test probability of deep vein thrombosis (DVT) to guide imaging and anticoagulation decisions.
Rules out pulmonary embolism in patients with low clinical suspicion, avoiding D-dimer and imaging.
Differentiates exudative from transudative pleural effusions using protein and LDH ratios from simultaneous pleural fluid and serum samples.
Calculates stroke risk for patients with non-valvular atrial fibrillation to guide anticoagulation therapy.
Estimates the 1-year risk of major bleeding in patients with atrial fibrillation starting anticoagulation.
Predicts 14-day mortality and cardiac events in patients with unstable angina or NSTEMI.
Identifies acute myocardial infarction in the presence of a Left Bundle Branch Block (LBBB) or paced rhythm.
Predicts in-hospital and 6-month mortality in patients with acute coronary syndrome (ACS).
Simplified protocol for ruling out PE using D-dimer with variable thresholds.
Simple ratio of heart rate to systolic blood pressure to screen for occult shock.
The gold-standard tool for assessing the level of consciousness in patients with acute brain injury or medical illness.
Standardized tool for measuring stroke severity and predicting patient outcomes.
Determines the need for head CT in patients with minor head injury and a GCS of 13–15.
Predicts the short-term risk of stroke after a Transient Ischemic Attack (TIA).
Alternative decision rule to the Canadian CT Head Rule for blunt head injury.
Grading scale for clinical severity of subarachnoid hemorrhage (SAH).
Grading system for SAH based on CT appearance to predict risk of delayed cerebral ischemia (vasospasm).
Differentiates between peripheral and central (stroke) causes of acute vestibular syndrome.
Los Angeles Motor Scale for field or ED triage of large vessel occlusion (LVO) in stroke.
Standardized scale for measuring the degree of disability or dependence in patients after a stroke.
Determines the need for ankle or midfoot X-rays after acute injury to exclude clinically significant fractures.
Clinically clears the cervical spine in trauma patients without the need for imaging.
A highly sensitive decision tool to determine the need for cervical spine imaging in alert trauma patients.
Rules for determining which patients with acute knee injuries require X-rays to rule out fracture.
Alternative to Ottawa Knee Rules for determining if a knee X-ray is required.
An anatomical scoring system that provides an overall score for patients with multiple injuries, calculated as the sum of the squares of the top 3 AIS region scores.
A physiological scoring system used for triage and to predict survival in trauma patients.
Identifies blunt trauma patients who can safely avoid chest CT imaging.
Predicts the probability of the need for massive transfusion in trauma patients.
Guides the interpretation of Focused Assessment with Sonography for Trauma findings.
Decision tool to identify children at very low risk of clinically-important traumatic brain injury (ciTBI) for whom CT imaging can be avoided.
Classifies the severity of croup in pediatric patients to guide management and treatment decisions.
Standardized assessment of newborn health at 1 and 5 minutes after birth.
Helps clinicians identify children at very low risk for intra-abdominal injury requiring intervention (IAI-I) after blunt torso trauma.
Sequential approach to identify febrile infants aged 21–90 days at low risk of invasive bacterial infection (IBI).
Identifies febrile infants ≤ 60 days old who are at low risk for serious bacterial infection (SBI).
Rules out bacterial meningitis in children with pleocytosis to avoid unnecessary antibiotics and hospitalization.
Calculates the probability of Group A Strep (GAS) pharyngitis in children and adults.
Risk-stratifies infants following an event involving changes in breathing, color, or muscle tone.
Modified GCS for children, particularly pre-verbal infants, to assess neurological status and coma depth.
Predicts mortality in community-acquired pneumonia (CAP) to help determine inpatient vs. outpatient management.
Estimates the probability of Group A Beta-hemolytic Streptococcus (GABHS) pharyngitis in patients with a sore throat.
Identifies patients with suspected infection who are at high risk for poor outcomes outside the ICU.
Defines Systemic Inflammatory Response Syndrome (SIRS) for screening for potential sepsis or infection.
Calculates the alveolar-arterial oxygen gradient to determine the cause of hypoxia.
Risk stratification tool to determine mortality and level of care for community-acquired pneumonia.
Determines the need for CTPA in pregnant patients with suspected pulmonary embolism using a variable D-dimer threshold.
Predicts mortality risk in patients with Chronic Obstructive Pulmonary Disease (COPD).
Self-assessment tool used to grade the severity of breathlessness in COPD and other chronic lung diseases.
Calculates the difference between measured cations and anions to differentiate causes of metabolic acidosis.
Adjusts total serum calcium for low albumin levels to estimate the physiologically active ionized calcium.
Adjusts measured sodium in the setting of hyperglycemia to determine the true hydration status. Supports both the standard Katz correction factor (1.6) and the Hillier correction factor (2.4) for severe hyperglycemia.
Calculates the volume of free water needed to correct hypernatremia.
Differentiates between pre-renal azotemia and acute tubular necrosis (ATN) in the setting of oliguria.
Calculates the fraction of filtered urea excreted in the urine — preferred over FENa for AKI differentiation in patients on diuretics.
Calculates the expected PaCO₂ compensation for a metabolic acidosis — used to determine if a concurrent respiratory acid-base disorder is present.
Estimates the amount of sodium bicarbonate (in mEq) required to correct a metabolic acidosis to a target HCO₃⁻ level.
Calculates the difference between measured serum osmolality and calculated osmolality — elevated gap suggests the presence of unmeasured osmoles (toxic alcohols, mannitol).
Calculates the hourly maintenance IV fluid rate using the Holliday-Segar method: 4 mL/kg/hr for the first 10 kg, 2 mL/kg/hr for the next 10 kg, and 1 mL/kg/hr for each kg thereafter.
Estimates the concentration of solutes in the blood. Used to calculate the osmolal gap when toxic alcohol ingestion is suspected.
Estimates urine ammonium excretion to differentiate renal from gastrointestinal causes of normal anion gap metabolic acidosis (NAGMA).
Identifies the cause of hypomagnesemia by determining whether the kidneys are appropriately retaining or inappropriately wasting magnesium.
Corrects the reticulocyte count for the degree of anemia and reticulocyte maturation time to assess whether the bone marrow response to anemia is adequate.
Determines the need for N-acetylcysteine (NAC) based on serum acetaminophen level and time since ingestion.
Calculates the continuous IV infusion rate for naloxone in opioid overdose requiring sustained reversal.
Determines the number of DigiFab vials required to treat life-threatening digoxin toxicity.
Converts various opioid dosages into a standardized morphine equivalent to assess overdose risk and guide safe prescribing.
Weight-based dosing protocol for fomepizole in the treatment of ethylene glycol or methanol poisoning.
Calculates the maximum safe dose of local anesthetic to prevent Local Anesthetic Systemic Toxicity (LAST).
Converts between equivalent doses of common corticosteroids based on relative glucocorticoid potency.
Provides approximate dose equivalents for common benzodiazepines to guide rotation or withdrawal management.
Adjusts measured phenytoin levels for hypoalbuminemia or renal failure to estimate the true free fraction.
Calculates manual IV infusion drip rates in drops per minute for gravity-based infusion.
Screens patients with upper GI bleeding to identify those at low risk who can be safely managed as outpatients.
Predicts mortality in patients with acute pancreatitis based on clinical and laboratory values at admission and at 48 hours.
Assesses the prognosis and 1- to 2-year survival of patients with liver cirrhosis.
Calculates the 3-month mortality risk for patients with chronic liver disease, used for transplant prioritization.
Calculates mortality risk and identifies patients with alcoholic hepatitis who may benefit from corticosteroid therapy.
Bedside Index for Severity in Acute Pancreatitis — a simple 5-point tool to identify patients at increased risk for in-hospital mortality.
Identifies patients with acute lower gastrointestinal bleeding who are at low risk of adverse outcomes and safe for discharge.
MANTRELS score — estimates the probability of acute appendicitis based on clinical symptoms, signs, and lab findings.
Estimates rebleeding risk and mortality in patients with upper GI bleeding following endoscopic assessment.
Categorizes peptic ulcers based on endoscopic appearance to predict rebleeding risk and guide hemostasis decisions.
Clinical Institute Withdrawal Assessment for Alcohol (Revised) — quantifies the severity of alcohol withdrawal and guides pharmacotherapy decisions.
Clinical Opiate Withdrawal Scale — quantifies opioid withdrawal severity to guide timing of buprenorphine induction and clinical management.
Columbia Suicide Severity Rating Scale (Screener) — a structured clinical interview tool to identify suicidal ideation and behavior and stratify risk.
Standardized 10-level scale to assess sedation and agitation in ICU patients, guide sedation titration, and facilitate daily awakening trials.
A 4-item screening tool for alcohol use disorder using the mnemonic CAGE: Cut down, Annoyed, Guilty, Eye-opener.
9-item validated screening and severity tool for major depressive disorder based on DSM criteria.
7-item validated tool for screening and measuring the severity of generalized anxiety disorder (GAD).
10-item validated screening tool for drug use problems (excluding alcohol and tobacco) over the past 12 months.
3-item abbreviated version of the full AUDIT focused on alcohol consumption frequency and quantity — highly sensitive for hazardous and heavy drinking.
4-item screening tool for intimate partner violence (IPV) using the mnemonic HARK: Humiliation, Afraid, Rape, Kick.
Estimates the Total Body Surface Area (TBSA) affected by second- and third-degree burns in adults.
Calculates the volume of Lactated Ringer's solution required for the first 24 hours of fluid resuscitation in adult burn patients.
Laboratory Risk Indicator for Necrotizing Fasciitis — uses six lab values to distinguish necrotizing fasciitis from severe cellulitis or other soft tissue infections.
Emergency Severity Index — a 5-level triage algorithm that classifies ED patients by acuity and anticipated resource utilization.
Quantifies the degree of organ dysfunction across 6 organ systems in critically ill patients and defines sepsis when score increases ≥ 2 from baseline.
Predicts the likelihood that biochemical thyrotoxicosis represents thyroid storm (a life-threatening endocrine emergency) versus uncomplicated thyrotoxicosis.
Differentiates patients with heparin-induced thrombocytopenia (HIT) from those with other causes of thrombocytopenia by quantifying pre-test probability.
Identifies chest pain patients who are low risk and safe for early discharge without further evaluation for ACS.
Quantifies the likelihood of an underlying vascular etiology (AVM, aneurysm, cavernous malformation, dural AVF, or tumor) as the secondary cause of intracerebral hemorrhage.
Determines the severity and mortality risk of upper gastrointestinal bleeding using only clinical variables available before endoscopy, enabling early risk stratification.
Predicts the likelihood of appendicitis in pediatric patients using clinical and laboratory findings, aiding in diagnosis and guiding imaging decisions.
Assesses pain in critically ill patients who cannot self-report by observing behavioral and physiological indicators across four domains.
Predicts large vessel occlusion (LVO) in patients with acute stroke symptoms to guide prehospital triage and direct transport to thrombectomy-capable centers.
A brief 3-item validated screening tool for suicidal ideation and recent suicide attempts in adult emergency department patients.
Predicts 90-day mortality risk in cancer patients diagnosed with acute pulmonary embolism to guide intensity of treatment and disposition.
Predicts risk of mortality or acute kidney injury (AKI) requiring renal replacement therapy in patients with rhabdomyolysis.
Doses high-dose regular insulin for toxicological management of calcium-channel blocker (CCB) and beta-blocker (BB) overdose causing cardiogenic shock.
Predicts 30-day unplanned readmission or death after hospital discharge in patients admitted to medicine or surgery wards.
Determines the need for chest X-ray imaging in patients with blunt chest trauma by identifying low-risk patients who can safely forgo radiography.
Doses atropine for life-threatening cholinergic toxicity caused by cholinesterase inhibitors including organophosphate and carbamate pesticides, nerve agents (Sarin, VX), and reversible acetylcholinesterase inhibitors.
Predicts in-hospital mortality in patients with pleural infection (empyema or complicated parapneumonic effusion) to guide intensity of treatment and need for early surgical drainage.
Predicts the likelihood of successful extubation in mechanically ventilated patients. Used as one component of a comprehensive spontaneous breathing trial assessment.
Identifies low-risk chest pain patients who can be safely evaluated for early discharge after a 2-hour accelerated diagnostic protocol.
Predicts large vessel occlusion (LVO) and severe stroke in the prehospital setting to guide triage and direct transport to thrombectomy-capable stroke centers.
Identifies patients after minor head trauma with loss of consciousness who are unlikely to require CT imaging, based on high-risk clinical criteria.
Estimates blood alcohol concentration (BAC) based on amount of alcohol ingested, patient weight, sex, and time elapsed since last drink using the Widmark formula.
Predicts the risk of Symptomatic Intracerebral Hemorrhage (sICH) in ischemic stroke patients receiving IV thrombolysis (tPA), to guide shared decision-making regarding thrombolytic therapy.
Predicts 30-day risk of serious adverse events (SAE) in ED patients presenting with syncope to identify those who require hospital admission or expedited investigation.
Rules out aortic dissection by stratifying pre-test probability based on high-risk conditions, pain features, and physical examination findings.
Predicts good functional outcome (mRS 0–2) at 90 days in patients with anterior circulation large vessel occlusion (LVO) strokes treated with endovascular therapy (EVT).
Classifies the severity of aneurysmal subarachnoid hemorrhage based on CT findings to predict symptomatic cerebral vasospasm risk.
An Accelerated Diagnostic Protocol (ADAPT) that identifies chest pain patients at 2 hours who are at low risk of major adverse cardiac events (MACE), enabling safe early ED discharge.
A validated accelerated diagnostic protocol combining the HEART Score with serial troponins to identify emergency department patients with acute chest pain who are safe for early discharge.
Rules out subarachnoid hemorrhage in neurologically intact adult patients presenting to the ED with a new severe headache reaching maximum intensity within one hour of onset.
Stratifies ACS risk using only clinical history and ECG findings — without initial troponin — to allow early risk stratification before laboratory results are available.
Rules out acute coronary syndrome using a single high-sensitivity troponin measurement combined with clinical history variables, enabling rapid ACS evaluation at presentation.
Distinguishes ventricular tachycardia (VT) from supraventricular tachycardia with aberrant conduction (SVT-A) in patients presenting with wide complex tachycardia (WCT).
Assesses level of consciousness in critically ill and comatose patients across four domains: Eye response, Motor response, Brainstem reflexes, and Respiration. Detects brain death and evaluates neurological function in intubated patients where GCS verbal component is unavailable.
Predicts in-hospital mortality in adult emergency department patients using six physiologic parameters: age, mean arterial pressure, heart rate, respiratory rate, oxygen saturation, and Glasgow Coma Scale. Provides rapid bedside risk stratification without requiring laboratory tests.
Estimates 30-day all-cause mortality in patients with ST-elevation myocardial infarction (STEMI) using clinical variables at presentation. Guides risk stratification and intensity of reperfusion and adjunctive therapy.
Predicts the likelihood of limb amputation in patients with severely injured extremities based on four factors: skeletal/soft tissue injury severity, degree of limb ischemia (doubled if >6 hours), hemodynamic shock, and patient age. Helps guide early amputation vs. limb-salvage decisions.
Estimates the probability of heparin-induced thrombocytopenia (HIT) using clinical and laboratory criteria evaluated by expert clinicians. Developed as a more granular alternative to the 4Ts score for identifying patients who warrant HIT antibody testing.
Predicts in-hospital mortality risk for ICU patients using 12 acute physiology variables, age, and chronic health status. The most widely used general ICU severity-of-illness scoring system worldwide.
Identifies acutely ill adult patients at risk of clinical deterioration, cardiac arrest, or unexpected ICU admission using six physiologic parameters. Standardizes early warning and escalation across hospital settings to trigger timely clinical review.
A bedside dysphagia screening tool for stroke patients that identifies those at high risk for aspiration and unsafe oral intake. Consists of neurological assessment followed by a 3-ounce water swallow test. A failed screen mandates NPO status and formal swallowing evaluation.
Classifies COPD severity based on post-bronchodilator spirometry (FEV1/FVC and FEV1 % predicted) and integrates exacerbation history and symptom burden (CAT/mMRC) to assign GOLD ABE groups for guiding pharmacologic therapy.
Estimates the optimal endotracheal tube (ETT) insertion depth at the lip using height-based formulas, and calculates the ideal tidal volume range for lung-protective ventilation based on ideal body weight (IBW). Prevents right mainstem intubation and ventilator-induced lung injury.
Assesses the severity of acute asthma exacerbations in pediatric patients using five clinical parameters. Guides treatment decisions for bronchodilator therapy, corticosteroids, and disposition (discharge vs. admission vs. ICU) in children with acute wheezing.
Identifies patients with acute heart failure presenting to the emergency department who are at high risk for serious adverse events (death, respiratory intubation, or return visit requiring hospitalization) within 30 days. Low-risk patients may be safely managed with early outpatient care.
Predicts 30-day PE-related complications (hemodynamic collapse, death from PE, or recurrent PE) in hemodynamically stable (normotensive) patients with acute pulmonary embolism. Stratifies intermediate-risk PE into low, intermediate-high, and high stages to guide intensity of monitoring and treatment.
Predicts in-hospital mortality in patients admitted with acute exacerbations of COPD (AECOPD). Guides decisions regarding ICU admission, early discharge, and palliative care using five easily obtained clinical variables.
Predicts in-hospital mortality and risk of mechanical ventilation in patients with acute exacerbations of COPD (AECOPD) using four readily available variables: BUN, altered mental status, pulse rate, and age ≥ 65. Provides a simple bedside risk stratification tool for US hospital populations.
Classifies the severity of inhalation injury in burn and smoke inhalation patients based on direct bronchoscopic visualization of airway findings. Provides an objective grade (0–4) that correlates with ventilator days, ICU length of stay, and mortality. Guides airway management and intensive care decisions.
Defines systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock based on clinical parameters. Provides the classic Sepsis-2 (2001) framework alongside the current Sepsis-3 (2016) definitions using SOFA/qSOFA for rapid bedside identification.
A rapid, bedside screening tool for identifying adult patients with suspected infection who are at high risk for in-hospital mortality and ICU admission outside of intensive care settings. Uses three clinical variables requiring no laboratory tests.
A 10-point topographic CT score of the MCA territory that quantifies the extent of early ischemic changes in anterior circulation stroke. Lower scores reflect greater ischemic burden and predict worse clinical outcome after reperfusion therapy. Used to select patients for IV thrombolysis and mechanical thrombectomy.
A 5-point clinical prediction rule developed from UK primary care to guide antibiotic prescribing in adults and children presenting with acute sore throat. FeverPAIN stratifies the probability of Group A Streptococcus (GAS) pharyngitis and recommends immediate antibiotics, delayed prescribing, or no antibiotics based on the score. Validated in the DESCARTE and PRISM trials.
A 5-variable clinical prediction score that estimates the probability of functional independence (modified Rankin Scale ≤2) at 90 days following spontaneous intracerebral hemorrhage (ICH). The FUNC score uses ICH volume, patient age, ICH location, Glasgow Coma Scale score at presentation, and presence of pre-ICH cognitive impairment to guide prognosis and treatment decisions.
A validated risk stratification tool for adult cancer patients with febrile neutropenia (FN) that identifies low-risk patients who may be suitable for oral antibiotic therapy or early discharge. Developed and validated by the Multinational Association for Supportive Care in Cancer (MASCC). A score ≥21 identifies patients at low risk for serious medical complications.
A 7-variable clinical scoring tool that predicts ADAMTS13 activity < 10% (severe deficiency) and thus the probability of immune-mediated thrombotic thrombocytopenic purpura (TTP) in adults presenting with thrombotic microangiopathy (TMA). The PLASMIC score enables rapid risk stratification to guide initiation of plasma exchange before ADAMTS13 results are available, which may take 24–72 hours.
A validated clinical scoring tool for estimating the risk of major bleeding events in patients with atrial fibrillation (AF) who are receiving oral anticoagulation therapy. Developed from the ORBIT-AF registry, the score uses five clinical variables to stratify patients into low, medium, and high bleeding risk categories, informing decisions about anticoagulation intensity and monitoring frequency.
A rapid, 4-variable bedside scoring tool that identifies trauma patients at highest risk of requiring massive transfusion (MT) — defined as ≥10 units of packed red blood cells in 24 hours. The ABC (Assessment of Blood Consumption) score is derived from immediately available clinical and ultrasound variables and is designed to be calculated within minutes of trauma patient arrival, enabling early activation of massive transfusion protocols (MTP).
A validated 5-parameter physiological scoring system that enables rapid bedside identification of deteriorating adult inpatients who may require urgent medical review or transfer to higher-acuity care. MEWS aggregates objective vital sign and consciousness data into a single score to standardize early recognition of clinical deterioration across general ward settings.
A spot urine test that estimates daily urinary protein excretion without requiring a cumbersome 24-hour urine collection. The urine protein-to-creatinine ratio (UPCR) correlates closely with 24-hour urine protein (in grams/day) and is used to classify proteinuria severity, screen for nephropathy, monitor renal disease progression, and assess response to therapy.
A 4-variable electrocardiographic formula developed by Dr. Stephen Smith (Hennepin County Medical Center) to distinguish subtle anterior STEMI from benign early repolarization (BER) in patients with anterior ST elevation in leads V1–V4 without obvious STEMI criteria. The formula quantifies ECG features to identify LAD occlusion in patients who would otherwise be misdiagnosed as BER and sent home.
The original CHADS₂ score estimates stroke risk in patients with non-valvular atrial fibrillation to guide anticoagulation therapy. Precedes CHA₂DS₂-VASc and remains widely cited in older guidelines.
A clinical classification system for pulmonary injury severity in patients who have survived blast or explosion exposure. Blast lung injury (BLI) is the most lethal form of primary blast injury and results from high-intensity pressure waves transmitted to the lungs. The severity score grades injury into mild, moderate, and severe categories based on oxygenation, chest imaging, and clinical parameters to guide ventilatory and resuscitative management.
The ICH Score (Hemphill 2001) estimates 30-day mortality in patients with spontaneous intracerebral hemorrhage based on five immediately available clinical and CT variables. It is the most widely used ICH outcome prediction tool.
A clinical decision rule derived from pediatric patients in Lyme disease-endemic areas that identifies children at low risk of bacterial meningitis who likely have Lyme neuroborreliosis, thereby potentially avoiding empirical antibacterial therapy and unnecessary lumbar punctures. Uses three '7' thresholds: CSF lymphocytes, duration of fever, and presence of 7th cranial nerve palsy.
Classifies severity of heart failure and cardiogenic shock in the setting of acute myocardial infarction (AMI) based on physical examination findings. Predicts in-hospital mortality.
The PESI score predicts 30-day outcome (mortality and serious adverse events) in patients with acute pulmonary embolism using 11 clinical variables. It stratifies patients into 5 risk classes to guide disposition decisions. The simplified version (sPESI) uses only 6 variables.
A 6-variable simplified version of the original Pulmonary Embolism Severity Index (PESI) that rapidly stratifies patients with confirmed acute pulmonary embolism (PE) into low-risk and high-risk categories for 30-day mortality. A score of 0 identifies low-risk patients who may be suitable for outpatient treatment or early discharge. Derived from the European Society of Cardiology PE guidelines and validated in multiple international datasets.
A validated 6-variable risk score for predicting major hemorrhagic complications in patients with venous thromboembolism (VTE — deep vein thrombosis or pulmonary embolism) who are receiving anticoagulation therapy. Derived from the RIETE (Registro Informatizado de la Enfermedad TromboEmbólica) registry, the score helps quantify the risk-benefit balance of anticoagulation, guide intensity and duration of therapy, and identify patients requiring close monitoring.
Predicts annual risk of major bleeding in patients with atrial fibrillation on warfarin anticoagulation. Uses five clinical variables from the ATRIA study cohort.
Stratifies in-hospital major bleeding risk following non-ST-elevation acute coronary syndrome (NSTE-ACS). Uses eight clinical variables available at time of admission.
Calculates mean arterial pressure — the average arterial pressure throughout one cardiac cycle. MAP is a fundamental hemodynamic parameter used to assess organ perfusion pressure and guide vasopressor therapy in shock states, sepsis, and traumatic brain injury.
The EGSYS (Evaluation of Guidelines in SYncope Study) score predicts cardiac etiology in patients presenting with syncope. A score ≥3 suggests a cardiac cause.
Calculates the heart-rate corrected QT interval (QTc) using the Bazett formula. QTc prolongation is a risk factor for torsades de pointes (TdP) and sudden cardiac death. Used to screen for congenital long QT syndrome, monitor drug-induced QT prolongation, and assess electrolyte-related cardiac risk.
The OESIL (Osservatorio Epidemiologico sulla Sincope nel Lazio) score estimates 12-month all-cause mortality in patients presenting with syncope to the emergency department.
Calculates the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO₂/FiO₂), the primary metric for classifying ARDS severity and assessing oxygenation failure in mechanically ventilated and spontaneously breathing patients. The P/F ratio provides a normalized measure of oxygenation independent of the level of oxygen supplementation.
The ROSE (Risk stratification Of Syncope in the Emergency department) rule identifies ED syncope patients at 1-month risk of serious outcomes (death, return ED visit for serious condition, or need for serious intervention) using a rapid assessment of 6 variables.
Calculates body surface area (BSA) using the Mosteller formula — the most widely used method in clinical practice. BSA is used for chemotherapy dosing, cardiac output indexing (cardiac index), pediatric drug dosing, burn management, and renal function reporting.
Identifies ED syncope patients at high risk for a serious outcome (death, MI, arrhythmia, PE, stroke, subarachnoid hemorrhage, significant hemorrhage, or any condition requiring hospitalization) within 7 days.
Calculates estimated glomerular filtration rate (eGFR) using the 2021 CKD-EPI creatinine equation. The 2021 CKD-EPI equation is the KDIGO-recommended formula for adults and eliminates the race coefficient previously used in older versions, providing a single race-neutral calculation. Used for CKD staging, drug dose adjustment, and renal function monitoring.
Calculates low-density lipoprotein (LDL) cholesterol using the Friedewald equation when a direct LDL measurement is not available. The Friedewald equation is the standard formula used in most laboratory lipid panel reports: LDL = Total Cholesterol − HDL − (Triglycerides / 5).
Predicts 3-month outcome (dead or dependent, modified Rankin Scale 5–6) in ischemic stroke patients receiving intravenous tPA. Allows pre-treatment prognostication.
A validated screening tool to distinguish acute stroke and TIA from non-stroke stroke mimics in the emergency department setting.
A validated risk stratification model for venous thromboembolism (VTE) in surgical patients, stratifying individuals into very low, low, moderate, and high risk categories to guide perioperative thromboprophylaxis decisions. The Caprini score assigns points based on clinical risk factors across multiple domains and is validated for general, vascular, plastic/reconstructive, and other surgical specialties.
A validated 11-item clinical scoring system for predicting the risk of venous thromboembolism (VTE) in hospitalized medical patients. The Padua score stratifies patients into low-risk (<4 points) and high-risk (≥4 points) groups, guiding pharmacological thromboprophylaxis decisions in non-surgical inpatients.
Stratifies 7-day stroke risk after transient ischemic attack (TIA) presentation in the emergency department. Uses clinical, laboratory, and imaging variables to guide admission vs. outpatient management.
Combines Glasgow Coma Scale (GCS) with pupil reactivity to improve prediction of in-hospital mortality and 6-month outcomes in traumatic brain injury patients. The Pupil Reactivity Score (PRS) is subtracted from GCS.
A validated 6-variable prediction rule for estimating the risk of major adverse cardiac events (MACE) in patients undergoing non-cardiac surgery. The RCRI (Lee Index) is the most widely used perioperative cardiac risk stratification tool, endorsed by ACC/AHA guidelines. It identifies patients who may benefit from cardiology evaluation, preoperative cardiac testing, or beta-blocker initiation before surgery.
An 8-item screening questionnaire for obstructive sleep apnea (OSA) validated for use in the general population, surgical preoperative assessment, and primary care. STOP-BANG assigns 1 point per positive item and classifies patients into low (0–2), intermediate (3–4), or high (5–8) risk for moderate-to-severe OSA. It is the most widely used OSA screening tool internationally.
Differentiates Reversible Cerebral Vasoconstriction Syndrome (RCVS) from other causes of thunderclap headache and intracranial arteriopathy, particularly CNS vasculitis. Higher scores favor RCVS diagnosis.
A validated 8-item self-administered questionnaire that measures daytime sleepiness by asking respondents to rate the likelihood of dozing off in eight different everyday situations. The ESS provides a measure of a person's general level of daytime sleepiness — an important symptom of sleep disorders including obstructive sleep apnea (OSA), narcolepsy, and idiopathic hypersomnia.
Predicts risk of symptomatic intracranial hemorrhage (sICH) after IV alteplase (tPA) for ischemic stroke. Helps inform shared decision-making and post-tPA monitoring intensity.
A validated 8-variable clinical decision rule for stratifying pre-test probability of pulmonary embolism (PE) in the emergency department and outpatient settings. The Revised Geneva Score uses only objective clinical parameters, eliminating the need for arterial blood gas analysis required by the original Geneva Score. It stratifies patients into low, intermediate, or high PE probability, guiding decisions about D-dimer testing and CT pulmonary angiography.
Estimates the 5-year risk of rupture of an unruptured intracranial aneurysm based on patient and aneurysm characteristics. PHASES = Population, Hypertension, Age, Size of aneurysm, Earlier SAH, Site.
Predicts probability of seizure occurrence in critically ill patients without clinically apparent seizures based on EEG and clinical features. Aids decisions about continuous EEG monitoring duration and initiation of empiric antiepileptic therapy.
Calculates the age-adjusted D-dimer threshold for pulmonary embolism (PE) exclusion. The standard D-dimer threshold of 500 µg/L FEU has high sensitivity but low specificity in older adults, leading to unnecessary CT pulmonary angiography. The age-adjusted threshold (age × 10 µg/L FEU for patients ≥50 years) was validated in the ADJUST-PE study and maintains safety while reducing imaging rates by approximately 30% in elderly patients with low-to-intermediate PE probability.
A broad set of criteria developed to identify ED syncope patients who require hospital admission. More sensitive than the San Francisco Syncope Rule, designed to ensure no high-risk patients are missed.
The Berlin Definition (2012) is the internationally accepted diagnostic framework for acute respiratory distress syndrome (ARDS). It replaced the 1994 American-European Consensus Conference (AECC) definition, which had poor inter-rater reliability and ambiguous criteria. The Berlin definition requires 3 prerequisite criteria (timing, chest imaging, origin of edema) and classifies ARDS severity into mild, moderate, and severe based on the PaO2/FiO2 (P/F) ratio with a minimum PEEP of 5 cmH₂O.
A validated 8-item clinical prediction rule for identifying patients with community-acquired pneumonia (CAP) at risk for requiring intensive respiratory or vasopressor support (IRVS). SMART-COP was derived from the Australian Community-Acquired Pneumonia Study and predicts the need for ICU-level interventions (mechanical ventilation or vasopressors) more accurately than PSI or CURB-65, which primarily predict 30-day mortality.
Estimates risk of drug-induced QTc prolongation (corrected QT interval ≥ 500 ms or ≥ 60 ms increase from baseline) in hospitalized patients. Facilitates identification of high-risk patients requiring closer ECG monitoring.
Established clinical criteria for diagnosing congestive heart failure. Diagnosis requires two major OR one major plus two minor criteria simultaneously, in the absence of alternative explanation.
The KDIGO (Kidney Disease: Improving Global Outcomes) 2012 staging system classifies acute kidney injury (AKI) into three stages based on serum creatinine changes and/or urine output. AKI is defined as any of: increase in serum creatinine ≥ 0.3 mg/dL within 48 hours; increase to ≥ 1.5× baseline within 7 days; or urine output < 0.5 mL/kg/h for ≥ 6 hours. Staging guides management intensity, nephrology consultation, and renal replacement therapy (RRT) decisions.
Classifies heart failure severity based on functional limitation. NYHA class correlates with mortality, guides therapy intensity, tracks treatment response, and affects clinical trial eligibility.
The KDIGO 2012 classification system for chronic kidney disease (CKD) uses eGFR and albuminuria to stage kidney disease severity and stratify risk for CKD progression, kidney failure, and cardiovascular complications. CKD is defined as abnormalities of kidney structure or function present for >3 months with health implications. Staging guides management intensity, nephrology referral, medication adjustment, and transplant evaluation.
Calculates 1-year stroke risk in patients with atrial fibrillation (AF). An alternative to CHA₂DS₂-VASc, the ATRIA score was developed from the ATRIA cohort and includes renal disease (substantial stroke risk modifier) as a distinct variable.
The King's College Criteria (KCC) identify patients with acute liver failure (ALF) who have a high risk of death without liver transplantation. Separate criteria exist for acetaminophen (APAP)-induced ALF and non-acetaminophen ALF. Meeting any single KCC criterion is a widely accepted threshold for urgent liver transplant listing evaluation. The KCC were derived from the King's College Hospital cohort (O'Grady et al., 1989) and have been externally validated worldwide.
Estimates ICU mortality probability using 17 physiologic and demographic variables collected within first 24 hours of ICU admission. Do not use to make treatment decisions for individual patients — a population-level prognostic tool.
The APRI (AST-to-Platelet Ratio Index) is a non-invasive serum-based index for estimating the degree of liver fibrosis and cirrhosis in patients with chronic liver disease, particularly chronic hepatitis C and hepatitis B. APRI is calculated as (AST/ULN_AST × 100) / platelet count (10⁹/L) and provides a simple, inexpensive alternative to liver biopsy for fibrosis staging when combined with clinical context. Endorsed by WHO guidelines for resource-limited settings.
The FIB-4 (Fibrosis-4) index is a non-invasive serum-based score for estimating liver fibrosis in patients with chronic liver disease, particularly hepatitis C, hepatitis B, and non-alcoholic fatty liver disease (NAFLD/MASLD). FIB-4 = (Age × AST) / (Platelet Count × √ALT) and performs consistently well across multiple chronic liver disease etiologies. It is the most widely validated non-invasive fibrosis marker for MASLD (metabolic dysfunction-associated steatotic liver disease).
Confusion Assessment Method adapted for ICU patients (CAM-ICU). A validated tool for detecting delirium in the ICU, including ventilated patients who cannot speak. Delirium is positive if features 1 AND 2 are present, PLUS either feature 3 OR feature 4.
The Lille Score predicts 6-month mortality in patients with severe alcoholic hepatitis (AH) who are receiving corticosteroid (prednisolone) therapy, by assessing response to treatment at Day 7. A Lille Score ≥ 0.45 identifies non-responders — patients who fail to demonstrate hepatic improvement on steroids — in whom continued steroid therapy is futile and associated with increased infection risk. First described by Louvet et al. (2007), the Lille Score is the standard clinical tool for 7-day steroid response assessment in severe AH.
Predicts survival to hospital discharge with intact neurological function following in-hospital cardiac arrest (IHCA) and CPR. Helps identify patients unlikely to survive CPR with neurologically intact outcome to guide code status discussions.
The Glasgow Alcoholic Hepatitis Score (GAHS) is a validated 5-variable clinical scoring tool for predicting 28-day and 84-day mortality in patients with severe alcoholic hepatitis. Developed by Forrest et al. (2005) at Glasgow Royal Infirmary, GAHS uses age, white cell count, blood urea nitrogen, prothrombin time ratio, and serum bilirubin. A score ≥ 9 identifies patients likely to benefit from corticosteroid therapy, and GAHS has been shown to be superior to Maddrey Discriminant Function for predicting steroid benefit.
Predicts in-hospital mortality in adults with COVID-19 on ED or hospital admission. Derived and validated from UK ISARIC cohort during the first wave. Variables: age, sex, comorbidities, respiratory rate, peripheral O₂ saturation, GCS, urea, and CRP.
Predicts the need for high-flow oxygen supplementation (≥ 6 L/min) or greater oxygen support within 24 hours of COVID-19 ED presentation. Useful for guiding disposition decisions — admission vs. discharge — in COVID-19 patients.
The MELD-Na (Model for End-Stage Liver Disease incorporating Sodium) is the current standard scoring system used by UNOS/OPTN for liver transplant organ allocation in the United States (adopted 2022). MELD-Na adds sodium-based correction to the original MELD score, improving mortality prediction in patients with hyponatremia-associated portal hypertension. It estimates 90-day liver-related mortality in patients with end-stage liver disease.
Predicts 30-day risk of serious adverse events (SAE) — death, intubation, ICU/hospital admission, BIPAP/NIV — in COPD patients presenting to the emergency department with acute exacerbation. Guides safe discharge versus admission decisions.
The Rotterdam CT Score is a validated prognostic tool for predicting 6-month mortality in patients with traumatic brain injury (TBI) based on initial CT head findings. It improves upon the Marshall CT Classification by adding epidural mass lesion status and subarachnoid/intraventricular hemorrhage as variables. Score range: 1–6, with higher scores predicting higher 6-month mortality. The Rotterdam Score predicts mortality complementary to admission GCS.
Quantifies the impact of COPD on a patient's health status and daily life using 8 patient-reported items. Guides treatment intensity according to GOLD guidelines (Groups A–D reclassification in GOLD 2023 as Groups A–E).
The Barthel Index (BI) is a widely used, validated ordinal scale measuring functional independence in activities of daily living (ADLs) in patients with neuromuscular or musculoskeletal disorders. Originally developed by Mahoney and Barthel (1965) for use in stroke rehabilitation, it assesses 10 functional domains with scores from 0 to 100. The Barthel Index guides rehabilitation planning, placement decisions, and serves as an outcome measure in stroke, TBI, and frailty assessment.
The Clinical Frailty Scale (CFS), developed by Rockwood et al. at Dalhousie University, is a rapid 9-point global assessment of frailty in older adults based on clinical judgment and observation. Unlike index-based frailty tools (Fried Frailty Phenotype), the CFS uses a simple narrative and pictographic description of activity level and health status, enabling rapid bedside assessment in 2–3 minutes. The CFS is now widely used in acute hospital, ICU, and emergency settings for frailty-adjusted risk stratification and prognostication.
Predicts in-hospital survival for adult patients receiving veno-venous ECMO (VV-ECMO) for acute respiratory failure. Guides patient selection and risk stratification for ECMO candidacy.
Predicts in-hospital survival for adult patients receiving veno-arterial ECMO (VA-ECMO) for refractory cardiogenic shock or cardiac arrest. Guides patient selection and risk communication for VA-ECMO candidacy.
The Charlson Comorbidity Index (CCI) is a weighted comorbidity scoring tool that predicts 10-year mortality based on the presence of 17 comorbid conditions. Each condition is assigned 1, 2, 3, or 6 points based on its relative risk of mortality. The CCI is widely used in clinical research, surgical risk stratification, oncology, and population health to adjust for comorbidity burden. An age-adjusted version adds points for each decade over age 40.
Assesses patient readiness for discharge from the post-anesthesia care unit (PACU) or recovery room. Evaluates five parameters: activity, respiration, circulation, consciousness, and color/oxygen saturation.
Kawasaki disease (KD) is an acute systemic vasculitis predominantly affecting children under 5 years, characterized by fever and mucocutaneous inflammation. It is the leading cause of acquired heart disease in children in developed countries due to coronary artery aneurysm formation. The AHA/AAP diagnostic criteria distinguish classic KD (fever ≥5 days + ≥4 of 5 principal features) from incomplete KD (fever + fewer features but laboratory and echocardiographic criteria support diagnosis).
The Pediatric Trauma Score (PTS) is a validated 6-component scoring system for rapid assessment of injury severity in children and triage to pediatric trauma centers. Each component is scored -1, +1, or +2, with a total range of -6 to +12. A PTS ≤ 8 indicates major pediatric trauma requiring treatment at a pediatric trauma center. The PTS was developed by Tepas et al. (1985) and validated as a triage tool for field and emergency department use.
Estimates annual major bleeding risk in patients with atrial fibrillation on anticoagulation. An alternative to HAS-BLED, used to guide anticoagulation decisions when 'HEMORR₂HAGES' variables are available.
The FLACC (Face, Legs, Activity, Cry, Consolability) Pain Scale is a validated behavioral observation pain assessment tool for children aged 2 months to 7 years, and for older children/adults who cannot self-report pain (developmental disability, sedation, mechanical ventilation). Each of 5 behavioral categories is scored 0–2, yielding a total score of 0–10. The FLACC scale is widely used in pediatric acute care, PACU, and ICU settings.
Diagnoses and grades the severity of post-thrombotic syndrome (PTS) in patients with prior deep vein thrombosis (DVT). PTS is a chronic venous insufficiency syndrome following DVT affecting up to 50% of DVT patients. Villalta score severity guides management decisions.
The Yale Observation Scale (YOS) is a validated clinical observation tool for assessing the degree of illness in febrile children aged 2 months to 2 years. It uses 6 behavioral items, each scored 1, 3, or 5 points, to generate a total score from 6 to 30. Higher scores indicate greater risk for serious bacterial infection (SBI). The YOS was developed by McCarthy et al. (1982) to help clinicians identify febrile infants and toddlers at risk for bacteremia, meningitis, and other serious infections.
Predicts risk of drug-resistant pneumonia (DRP) causative pathogens at time of pneumonia diagnosis. Distinguishes patients at high risk for drug-resistant organisms (MRSA, drug-resistant Gram-negatives, Pseudomonas) from those who can be treated with standard community-acquired pneumonia (CAP) regimens.
The Mini-Cog is a validated 3-minute dementia screening tool consisting of a 3-item word recall test and a clock drawing test (CDT). It is widely used in primary care, geriatrics, and hospital settings due to its brevity, minimal training requirements, and good sensitivity (76–99%) and specificity (89–93%) for detecting dementia across diverse populations. The Mini-Cog is less education-biased than the MMSE and performs well in non-English-speaking populations.
Diagnostic criteria for the initial attack of acute rheumatic fever (ARF) following Group A Streptococcal (GAS) pharyngitis. The 2015 AHA revised Jones criteria include stricter echocardiographic requirements and risk-stratification based on population rheumatic fever incidence.
Clinician-administered severity scale for major depressive disorder (MDD). The 17-item version (HAM-D 17) is the most widely used and validated form in clinical trials and practice. Assesses symptom severity in patients with established MDD diagnosis — not a screening or diagnostic tool.
The Bishop Score is a validated pelvic scoring system that assesses cervical readiness (ripeness) for labor induction. Developed by Bishop (1964), it evaluates 5 cervical and fetal station parameters to predict the likelihood of successful labor induction and estimate the probability of vaginal delivery. A higher Bishop Score indicates a more favorable (ripe) cervix and predicts more successful induction with shorter labor duration.
A clinical decision support tool for diagnosing preeclampsia and classifying its severity per 2020 ISSHP (International Society for the Study of Hypertension in Pregnancy) and ACOG criteria. Preeclampsia is defined as new-onset hypertension (SBP ≥140 or DBP ≥90 mmHg on ≥2 occasions ≥4 hours apart) after 20 weeks gestation, plus ≥1 feature of end-organ involvement. Severe features significantly increase maternal and fetal risk and often require delivery.
Predicts risk of aberrant drug-related behaviors in patients prescribed chronic opioid therapy for chronic non-cancer pain. Stratifies patients into low, moderate, and high risk prior to opioid prescribing. Enables risk mitigation strategies proportional to each patient's risk level.
The AUDIT (Alcohol Use Disorders Identification Test) is a validated 10-item WHO-developed screening questionnaire for identifying hazardous and harmful alcohol use, as well as probable alcohol dependence. Developed by Babor et al. for the World Health Organization (1992), the AUDIT is the most widely validated and internationally used alcohol screening tool, with high sensitivity (92%) and specificity (94%) for identifying hazardous drinking at the recommended threshold of ≥ 8.
Guides operative vs. non-operative management of thoracolumbar spine injuries based on three independent factors: morphology of injury, integrity of the posterior ligamentous complex (PLC), and neurological status. Developed and validated to reduce variability in thoracolumbar fracture management decisions.
Diagnostic scoring system for suspected acute appendicitis, developed to improve diagnostic accuracy in an Asian population where the Alvarado score has suboptimal performance. The RIPASA score uses 14 clinical, laboratory, and demographic variables to discriminate between appendicitis and non-appendicitis in adult patients presenting with acute right iliac fossa pain.
The PC-PTSD-5 is a 5-item self-report screening tool for post-traumatic stress disorder (PTSD) validated for use in primary care settings, consistent with DSM-5 criteria. It was developed by Prins et al. and is endorsed by the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD). Each item asks about PTSD symptoms in the past month, and a positive screen (≥3) indicates probable PTSD requiring further diagnostic assessment.
The PHQ-2 is an ultra-brief 2-item validated screening tool for major depressive disorder (MDD), derived from the longer PHQ-9. It asks about the two core symptoms of depression — anhedonia and depressed mood — over the past 2 weeks. Each item is scored 0–3, yielding a total score of 0–6. A PHQ-2 score ≥ 3 is the validated cutoff for a positive depression screen, prompting follow-up with the full PHQ-9. The PHQ-2 has sensitivity of 83% and specificity of 92% for MDD.
Appendicitis Inflammatory Response (AIR) score — a validated clinical prediction rule combining symptoms, signs, and inflammatory markers to stratify risk of acute appendicitis and guide surgical referral decisions. Developed in Sweden and validated in multiple populations with superior discrimination compared to the Alvarado score.
Patient-reported outcome measure for rheumatoid arthritis (RA) disease activity. RAPID3 is a 3-item multidimensional HAQ/RAQoL-derived tool that captures physical function, pain, and patient global assessment. Validated as a rapid alternative to DAS28 and CDAI in clinical practice.
The American Society of Anesthesiologists (ASA) Physical Status Classification is a standardized 6-category system for assessing a patient's preoperative health status and physiological reserve. Developed in 1963 and revised multiple times, the ASA classification is used universally in preoperative risk stratification, resource allocation, informed consent discussions, and perioperative outcome research. It correlates with surgical mortality, postoperative complications, and length of stay.
Standard clinical grading system for hepatic encephalopathy (HE) severity. Categorizes patients from Grade 0 (covert/minimal HE with subtle cognitive changes) to Grade 4 (deep coma). Used for clinical communication, treatment triage, and monitoring treatment response.
The Surgical Apgar Score (SAS) is a validated 3-item intraoperative scoring system for predicting major postoperative complications (death, need for reoperation, or life-threatening complications requiring ICU admission) within 30 days of surgery. Developed by Gawande et al. (2007), it uses estimated blood loss, lowest mean arterial pressure, and lowest heart rate recorded during the operation — information available at the end of any surgical procedure. Score range: 0–10; higher scores predict better postoperative outcomes.
Standard diagnostic criteria for infective endocarditis (IE) based on clinical, microbiological, and echocardiographic findings. The Modified Duke Criteria (2000 Li et al.) classify patients as Definite IE, Possible IE, or Rejected IE, guiding diagnostic workup intensity and treatment initiation.
The Nutritional Risk Screening 2002 (NRS-2002) is a validated 3-component screening tool for identifying hospitalized patients at nutritional risk who are likely to benefit from nutritional support. Developed by Kondrup et al. and endorsed by ESPEN (European Society for Clinical Nutrition and Metabolism), NRS-2002 combines a nutritional status score, a disease severity score (reflecting increased metabolic demand), and an age component. A total score ≥ 3 indicates nutritional risk requiring nutritional support.
The Baux Score is a simple clinical formula for estimating mortality risk in patients with thermal burn injuries. The original Baux Score = Age + %TBSA (Total Body Surface Area) of 2nd and 3rd degree burns. The Revised Baux Score adds 17 points for the presence of inhalation injury (reflecting its ~17% equivalent increase in predicted mortality). Originally described by Baux in 1961, it remains useful for rapid triage and prognosis estimation in burn patients.
Simplified clinical severity scoring tool for community-acquired pneumonia (CAP) in primary care and outpatient settings. A version of CURB-65 that omits urea (BUN) measurement — enabling assessment without blood tests. Stratifies into low, moderate, and high risk to guide disposition (home vs. hospital vs. ICU).
The Marshall CT Classification (Marshall et al., 1991) is a 6-category system for grading the severity of intracranial pathology on CT in patients with traumatic brain injury (TBI). It stratifies patients from Category I (no visible pathology) through Category VI (non-evacuated high-density lesion >25 mL) based on basal cistern status, midline shift, and the presence of mass lesions. The classification is predictive of mortality and poor neurological outcome and guides neurosurgical decision-making.
Predicts probability of successful vaginal birth after cesarean (VBAC). Based on 5 clinical factors available at the beginning of labor, the Flamm-Geiger model estimates the likelihood of successful trial of labor after cesarean (TOLAC) to guide counseling and clinical decision-making.
The ATLS (Advanced Trauma Life Support) Hemorrhagic Shock Classification stratifies hemorrhagic shock into four classes based on estimated blood loss, heart rate, blood pressure, respiratory rate, and mental status. Developed by the American College of Surgeons and integral to ATLS training, the classification guides initial fluid resuscitation, blood product transfusion, and surgical hemorrhage control decisions in trauma patients.
Clinical decision rule for identifying patients with acute flank pain who have an uncomplicated ureteral stone (without alternative serious diagnosis requiring CT). The STONE score (Sex, Timing, Origin, Nausea, Erythrocytes) helps clinicians decide when CT urography is necessary versus when clinical diagnosis of ureteral colic is sufficiently certain.
Estimates 10-year probability of hip fracture and major osteoporotic fracture (hip, wrist, humerus, spine) based on clinical risk factors. This version uses clinical variables only, without bone mineral density (BMD) — appropriate for initial screening. Countries have country-specific FRAX models; values here reflect a standardized North American approach.
The Pitt Bacteremia Score (PBS) is a validated 5-item clinical severity scoring system for quantifying illness severity in patients with bacteremia (bloodstream infection, BSI). Developed by Rhee et al. at the University of Pittsburgh, it measures temperature abnormality, hypotension requiring vasopressors, mechanical ventilation, cardiac arrest, and altered mental status — each reflecting clinical deterioration attributable to the severity of the BSI and host response. PBS correlates strongly with in-hospital mortality in bacteremic patients and is used in clinical studies to adjust for illness severity.
Scoring-based classification system for gout, jointly developed by the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) in 2015. Classifies patients as having or not having gout based on a weighted score integrating clinical, laboratory, and imaging data.
The Harris-Benedict Equation (revised by Mifflin-St Jeor variants also exist) is the original validated formula for estimating Resting Energy Expenditure (REE), also called Basal Metabolic Rate (BMR). The revised Harris-Benedict equations (Roza and Shizgal, 1984 revision) are: Men: REE = 88.362 + (13.397 × weight kg) + (4.799 × height cm) − (5.677 × age years); Women: REE = 447.593 + (9.247 × weight kg) + (3.098 × height cm) − (4.330 × age years). Total Daily Energy Expenditure (TDEE) = REE × activity factor. Harris-Benedict is widely used in clinical nutrition planning to estimate daily caloric requirements.
The Mehran Score is a validated 8-variable risk scoring system for predicting contrast-induced acute kidney injury (CI-AKI), defined as an increase in serum creatinine ≥0.5 mg/dL or ≥25% above baseline within 48–72 hours of iodinated contrast administration. Developed by Mehran et al. (2004) from a large percutaneous coronary intervention (PCI) database, the score quantifies pre-procedural risk to guide prophylactic strategies (IV hydration, N-acetylcysteine, contrast dose minimization) and to identify patients at highest risk for dialysis or prolonged hospitalization.
The Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria for SLE. An update to the ACR 1997 revised criteria, with improved sensitivity (97% vs. 83%) at the cost of slightly lower specificity (84% vs. 96%). Classification requires ≥ 4 criteria (≥ 1 clinical and ≥ 1 immunological) OR biopsy-confirmed lupus nephritis with ANA or anti-dsDNA positivity.
Validated objective severity scoring tool for acute asthma in children aged 2–17 years. PRAM assigns scores 0–12 based on five clinical assessments and accurately classifies mild, moderate, and severe exacerbations. Used in pediatric emergency departments to guide management intensity and track treatment response.
The Malnutrition Universal Screening Tool (MUST) is a validated 3-step screening tool for identifying adults at risk of malnutrition in community, outpatient, and inpatient settings. Developed by the Malnutrition Advisory Group (MAG) of the British Association for Parenteral and Enteral Nutrition (BAPEN), MUST assesses BMI, unintentional weight loss percentage over 3–6 months, and the presence of acute disease effect (illness preventing eating ≥5 days). Total score 0 = low risk; 1 = medium risk; ≥2 = high risk. The MUST is recommended by BAPEN, ESPEN, and NICE for routine nutritional screening in UK healthcare settings.
The World Federation of Neurosurgical Societies (WFNS) Subarachnoid Hemorrhage (SAH) Grading Scale is a 5-grade classification of clinical severity in patients with aneurysmal subarachnoid hemorrhage, based on the Glasgow Coma Scale (GCS) score and the presence or absence of focal motor deficits. Developed by Drake et al. and adopted by the WFNS, it is the most widely used SAH grading system in neurosurgical practice, correlating with surgical risk, neurological outcome, and vasospasm risk.
The 2024 Phoenix Sepsis Score — a novel, validated pediatric sepsis scoring system derived from the 2024 international consensus update on pediatric sepsis and septic shock definitions. Uses 4 organ system dysfunction domains weighted by clinical importance. Replaces the SIRS-based pSIRS definition as the new standard for pediatric sepsis classification.
The Mallampati Score (Modified Mallampati Classification) is a validated 4-class clinical tool for predicting difficult laryngoscopy and intubation by assessing the visibility of oropharyngeal structures. The patient is examined seated with head in neutral position, mouth fully open, tongue protruded maximally, and phonation avoided. The score correlates with the degree of tongue-to-pharyngeal space relationship: Class I = full visualization (easy intubation); Class IV = no oropharyngeal structures visible (potentially difficult intubation). A component of multiple difficult airway prediction tools (e.g., LEMON assessment, Naguib score).
A bedside tool for nurses and physicians to identify pediatric inpatients who are deteriorating and at risk of critical events, enabling early escalation before cardiac arrest or respiratory failure. Multiple versions exist; this implements the 3-domain Brighton Pediatric Early Warning Score format (behavior, cardiovascular, respiratory).
Classifies infants presenting with a brief resolved unexplained event (BRUE) into lower-risk or higher-risk groups to guide appropriate evaluation and management. BRUE (formerly ALTE — apparent life-threatening event) criteria were updated by AAP in 2016. Lower-risk BRUE infants can be managed with a limited evaluation and avoid unnecessary investigations.
The Adjusted Body Weight (ABW) formula is used in clinical practice for pharmacokinetic dosing and nutritional calculations in obese patients (BMI >30 kg/m²), where using actual total body weight (TBW) would overestimate drug distribution or caloric requirements, and using ideal body weight (IBW) would underestimate them. The formula ABW = IBW + 0.4 × (TBW − IBW) reflects the empirically derived estimate that approximately 40% of excess adipose tissue participates in drug distribution for lipophilic medications (e.g., aminoglycosides, vancomycin, digoxin). For hydrophilic drugs (e.g., heparin, neuromuscular blockers), IBW or lean body weight (LBW) is typically used.
A standardized assessment of functional status measuring independence in 6 basic activities of daily living (ADL). The Katz ADL Index is one of the most widely used tools for assessing physical function in elderly patients, informing care planning, prognosis, and rehabilitation goals.
Quantifies emergency department overcrowding level using 6 operational metrics. NEDOCS allows ED administrators, charge nurses, and physicians to objectively categorize operational crowding level, track trends, and trigger escalation protocols at defined thresholds.
A validated, 6-item screening tool for alcohol and drug use problems in adolescents aged 14–21. CRAFFT (Car, Relax, Alone, Forget, Friends, Trouble) is recommended by SAMHSA and AAP for primary care and ED adolescent substance use screening. Score ≥ 2 indicates high risk requiring intervention.
A validated 7-level single-item rating scale for assessing acute agitation severity in clinical settings. BARS was developed for emergency and psychiatric settings to standardize agitation documentation, guide treatment selection, and monitor treatment response. Simple enough to apply in seconds by any clinician.
A classification and treatment algorithm for subaxial (C3–C7) cervical spine injuries based on three domains: injury morphology, status of discoligamentous complex (DLC), and neurological status. SLICS guides surgical decision-making — whether to observe, brace, or operate. Higher SLICS scores indicate need for surgical intervention.
Predicts the risk of in-hospital cardiac arrest (IHCA) within 24 hours of vital sign measurement in hospitalized, non-ICU patients. CART uses 4 readily available clinical variables to identify ward patients at high risk for deterioration requiring rapid response or ICU transfer. Can be used as an adjunct to early warning score systems.
A clinical decision rule for identifying children at high risk of clinically important brain injury (ciBI) after closed head injury, determining when CT scan is warranted. Developed to reduce unnecessary radiation exposure from CT in pediatric head trauma while maintaining sensitivity for significant injuries.
Assesses spinal instability in patients with spinal metastases to guide the urgency of surgical spine consultation. SINS was developed to create a standard, reproducible framework for classifying spinal instability in oncology patients across disciplines — oncology, radiation oncology, and neurosurgery — and to identify patients who need surgical stabilization before or after radiation therapy.
A newer clinical probability score for pulmonary embolism (PE) that uses 4 clinical variables to stratify patients into low, intermediate, and high pre-test probability categories. 4PEPS was developed to simplify PE pre-test probability assessment compared to the Wells PE score while maintaining comparable diagnostic performance.
Predicts 30-day adverse outcomes (death or requirement for organ support such as ventilation, vasopressors, or renal replacement) in patients presenting to the emergency department with suspected COVID-19. The PRIEST score was developed and validated in multiple UK emergency departments during the first wave of the pandemic to assist with triage decisions.
Predicts 1-year risk of major bleeding in patients with atrial fibrillation enrolled in the Global Anticoagulant Registry in the FIELD (GARFIELD-AF) study. Developed to provide a complementary bleeding risk assessment alongside stroke risk estimation (CHA₂DS₂-VASc) to guide anticoagulation decisions in AF.
Identifies patients with Staphylococcus aureus bacteremia (SAB) at high risk for infective endocarditis (IE). VIRSTA was derived to help clinicians determine which patients with SAB require urgent transthoracic or transesophageal echocardiogram (TTE/TEE) for IE evaluation, as routine echocardiography of all SAB patients is resource-intensive.
Predicts the annual risk of recurrent venous thromboembolism (VTE) after first unprovoked VTE following anticoagulation discontinuation. DASH score identifies patients at low enough recurrence risk to safely discontinue anticoagulation after the minimum treatment period vs. those who should continue indefinite anticoagulation.
A physiological scoring system for initial trauma patient triage and outcome prediction, based on three physiological parameters: Glasgow Coma Scale (GCS), systolic blood pressure (SBP), and respiratory rate (RR). The Revised Trauma Score replaced the original Trauma Score (Champion et al., 1989) and is widely used for field triage and interhospital trauma transfer decision-making.
Estimates the risk of major in-hospital bleeding in acutely ill hospitalized medical patients to inform decisions about VTE pharmacoprophylaxis. The IMPROVE Bleeding Risk Score was developed from the multi-center international IMPROVE registry and is the companion tool to the IMPROVE VTE risk score.
Quantifies the risk of VTE (DVT and PE) in acutely ill hospitalized medical patients to guide pharmacological thromboprophylaxis decisions. Developed from the international IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) registry. Companion to IMPROVE Bleeding Score.
Predicts the risk of acute kidney injury (AKI) requiring dialysis after cardiac surgery (CABG and/or valve procedures). The Thakar clinical score was developed to provide pre-operative risk stratification for renal complications, inform patient counseling, and guide peri-operative nephrology involvement.
A validated 5-item behavioral observational scale for assessing pain intensity in patients with severe dementia who are unable to self-report. PAINAD evaluates breathing pattern, negative vocalization, facial expression, body language, and consolability to estimate pain level when verbal pain scales are unreliable.
A validated 7-factor severity scoring system for Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) that predicts in-hospital mortality. SCORTEN is the standard severity scoring tool for these rare but life-threatening mucocutaneous reactions. Higher SCORTEN correlates directly with mortality risk.
A clinical decision rule designed to identify women with unprovoked VTE who have a sufficiently low recurrence risk to safely discontinue anticoagulation after completing the minimum treatment period. HERDOO2 was developed in the REVERSE study to overcome the limitation that most VTE recurrence risk scores perform best in men — women with first unprovoked VTE have overall lower recurrence rates than men.
A clinical scoring tool for predicting 90-day mortality in patients with viral pneumonia, including COVID-19, influenza, other respiratory viruses. MuLBSTA uses 6 clinical variables to identify high-risk patients who may benefit from more aggressive support or ICU-level care.
Defines the American College of Obstetricians and Gynecologists (ACOG) diagnostic criteria for preeclampsia and severe features of preeclampsia during pregnancy. Updated in 2013 and refined in 2020 — proteinuria is no longer required for diagnosis if severe features are present.
Predicts the risk of right heart failure (RHF) requiring right ventricular assist device (RVAD) or sustained inotropes for > 14 days after left ventricular assist device (LVAD) implantation. Developed from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS).
Predicts the risk of deep vein thrombosis (DVT) or pulmonary embolism (PE) associated with peripherally inserted central catheter (PICC) placement. The Michigan PICC Score was derived to help clinicians determine when patients have sufficient VTE risk to justify post-insertion prophylactic anticoagulation — a practice with uncertain benefit and variable adoption.
Identifies patients with community-acquired pneumonia (CAP) at high risk for severe outcomes (ICU admission, mechanical ventilation, in-hospital mortality) using 8 clinical variables. SCAP simplifies ICU admission triage for CAP beyond CURB-65 by incorporating hemodynamic and radiographic severity features.
Identifies patients with diffuse large B-cell lymphoma (DLBCL) at high risk for CNS relapse and who may benefit from CNS prophylaxis. The CNS-IPI combines the 5 International Prognostic Index (IPI) variables with kidney/adrenal gland involvement to create a 6-factor risk score.
An enhanced prognostic score for diffuse large B-cell lymphoma (DLBCL) that improves upon the standard IPI by using age cutoffs (41–60, 61–75, > 75), distinguishing LDH levels (≥ 1–3× ULN vs. > 3× ULN), and including specific high-risk extranodal involvement. Derived from R-CHOP treated cohorts to better discriminate survival outcomes.
A standardized structured interview tool for quantifying bleeding history to diagnose bleeding disorders. Developed by the ISTH SSC (Scientific and Standardization Committee) to provide a reproducible measure of the bleeding phenotype across clinical studies. Normal score is 0–3 for adult women and 0–2 for men and children. Abnormal score suggests clinical bleeding disorder warranting further workup.
Predicts the risk of clinically relevant bleeding in patients with venous thromboembolism (DVT/PE) on anticoagulation therapy. VTE-BLEED was developed to identify patients at increased bleeding risk for whom extended anticoagulation carries higher risk/benefit uncertainty, and to support shared decision-making about duration of anticoagulation therapy.
Calculates the Absolute Neutrophil Count (ANC) from a complete blood count (CBC) with differential. ANC is the most clinically relevant measure for assessing infection risk in patients on myelosuppressive chemotherapy, stem cell transplant recipients, and patients with bone marrow failure syndromes. Neutropenia is defined as ANC < 1500 cells/μL in adults.
Identifies adult patients presenting to the emergency department with suspected infection who are at low risk for true bacteremia and for whom blood cultures may have limited clinical utility (low yield). The Shapiro rule defines major and minor criteria that, when positive, identify high-risk groups where blood cultures are clearly indicated. The absence of any major or minor criteria identifies a very low-risk group.
The PIRO score stratifies patients with community-acquired pneumonia (CAP) by severity and 28-day mortality using four domains: Predisposition, Insult, Response, and Organ dysfunction. Analogous to PIRO framework in sepsis. PIRO for CAP was developed in an ICU-level population as an adjunct to CURB-65 and PSI with better discrimination of critically ill patients.
Predicts HIV incidence risk in HIV-negative men who have sex with men (MSM) to guide pre-exposure prophylaxis (PrEP) counseling and prescription. HIRI-MSM was derived from US MSM cohorts to identify high-risk individuals most likely to seroconvert within 3 years who will benefit most from PrEP.
Predicts in-hospital mortality and severe acute pancreatitis using 5 bedside clinical variables collected within the first 24 hours of admission. Developed as a simpler alternative to Ranson's criteria and APACHE-II score. BISAP ≥ 3 is associated with significantly elevated mortality and organ failure rates.
Standardized diagnostic criteria for eosinophilic esophagitis (EoE) based on clinical presentation (dysphagia, food impaction, reflux-type symptoms) combined with endoscopic features (EREFS score: exudates, rings, edema, furrows, strictures) and histologic confirmation (≥ 15 eosinophils per high-power field on esophageal biopsy). EoE diagnosis requires symptom + histologic criteria with exclusion of other causes.
Predicts 90-day mortality risk after colorectal cancer resection using preoperative clinical variables. RESECT enables risk-stratified consent, optimized prehabilitation planning, and high-risk patient identification for enhanced recovery protocols. Score is calculated from 7 preoperative factors.
Identifies patients with acute kidney injury (AKI) who have clinical and laboratory features most consistent with acute interstitial nephritis (AIN) as opposed to other AKI etiologies (pre-renal, ATN, obstruction, glomerulonephritis). AIN accounts for 15–25% of AKI biopsies and is importantly a reversible cause if the offending drug or trigger is removed promptly. The score uses clinical and urinalysis features to support pre-biopsy risk stratification.
Calculates Kt/V (urea clearance × time / urea distribution volume), the primary measure of hemodialysis adequacy. Target Kt/V ≥ 1.4 per session (single-pool, spKt/V) for 3×/week hemodialysis per KDOQI guidelines. Inadequate dialysis is associated with increased cardiovascular mortality, hospitalization, and poor nutritional status in ESRD patients.
Calculates the recommended rate of serum sodium correction based on the Adrogue-Madias formula to guide safe hyponatremia management. The formula estimates the change in serum sodium per liter of intravenous fluid administered, accounting for the electrolyte content of the infusate and the patient's total body water. Overcorrection of chronic hyponatremia risks osmotic demyelination syndrome (ODS).
Calculates gestational age in weeks and days from the last menstrual period (LMP) date, or from the date of conception (IVF/known ovulation). Also calculates the estimated due date (EDD) using Naegele's rule (LMP + 280 days). Gestational age is one of the most fundamental obstetric calculations for obstetric risk stratification, fetal growth assessment, and timing of antenatal interventions.
Assesses the risk of preterm birth (PTB) in women presenting with symptoms of preterm labor, using a combination of cervical fetal fibronectin (fFN) biomarker, transvaginal cervical length measurement, and clinical risk factors. Helps guide triage decisions: admission, corticosteroids, tocolysis, and transfer to a tertiary center.
Assesses severity of acute asthma exacerbations in pediatric patients (ages 1–18 years) using three clinical components: respiratory rate, oxygen saturation, and auscultatory findings (wheeze/air entry). PASS is used in pediatric EDs for triage, initial severity classification, and response-to-treatment monitoring during bronchodilator therapy.
A clinical care model for assessing and managing Neonatal Opioid Withdrawal Syndrome (NOWS) that prioritizes infant feeding ability, sleeping behavior, and consolability over traditional numeric scoring scales (Finnegan NAS scale). The ESC approach has been shown to significantly reduce pharmacotherapy rates, NICU length of stay, and hospital costs while maintaining safety.
Assesses the severity of iatrogenic opioid and benzodiazepine withdrawal symptoms in pediatric ICU patients requiring weaning from sedoanalgesia. The WAT-1 (Withdrawal Assessment Tool Version 1) was developed by the PICU weaning collaborative and is validated in children aged 0–18 years who received ICU sedation for ≥ 5 consecutive days.
Defines the International Pediatric Sepsis Consensus Conference (IPSCC 2005) criteria for Systemic Inflammatory Response Syndrome (SIRS), sepsis, severe sepsis, and septic shock in children. Age-specific vital sign thresholds distinguish pediatric SIRS from the adult Sepsis-1/2 criteria. These definitions guide early recognition, escalation to critical care, and initiation of sepsis bundles in pediatric patients.
Evidence-based clinical decision rule to identify pediatric patients (age 0–17) with blunt trauma who can safely forgo cervical spine CT imaging. Derived from a large prospective PECARN (Pediatric Emergency Care Applied Research Network) multicenter study of over 4,000 pediatric patients with potential cervical spine injuries. High sensitivity for clinically important C-spine injuries.
Calculates estimated endotracheal tube (ETT) internal diameter for pediatric intubation using age-based formulas. Most commonly used formula for uncuffed ETT: (Age/4) + 4. For cuffed ETTs (preferred in modern PICU practice): (Age/4) + 3.5. Tube depth (cm at the lip) estimation: (Age/2) + 12. Multiple alternative formulas exist (Luten, weight-based). Broselow tape provides length-based ETT sizing for patients < 35 kg.
A validated 4-item screening tool for intimate partner violence (IPV) in primary care and emergency department settings. HITS asks about physical, emotional, and verbal abuse. A score ≥ 11 is a positive screen requiring safety assessment and referral. HITS was originally validated in adult female patients presenting to primary care and has subsequently been validated across multiple clinical settings and populations.
A 10-item brief screening instrument adapted for older adults (age ≥ 65) to detect alcohol use disorder. The SMAST-G (Geriatric) version uses age-appropriate language and scenarios more relevant to older adults' drinking context (drinking alone at home, memory issues) where standard CAGE and AUDIT may be less sensitive. Two or more positive responses constitutes a positive screen.
Calculates the Pediatric End-Stage Liver Disease (PELD) score for patients aged ≤ 11 years. Used by UNOS/OPTN to prioritize pediatric liver transplant waitlist allocation. The PELD score uses serum albumin, bilirubin, INR, growth failure status, and age < 1 year as parameters. Higher PELD score = higher 3-month mortality on waitlist = higher transplant priority. Patients ≥ 12 years use the MELD score system instead.
The Pediatric Appendicitis Risk Calculator (pARC) is a validated clinical prediction tool that estimates the probability of appendicitis in children without requiring laboratory tests or imaging in its base form. Inputs include eight clinical and basic laboratory variables. The pARC was derived from over 2,000 children (ages 5–18 years) in the PECARN network and provides a continuous probability estimate (0–100%) rather than a categorical score. It is among the most accurate non-ultrasound pediatric appendicitis predictors.
Assesses severity of Post-Acute Withdrawal Syndrome (PAWS) in patients recovering from alcohol use disorder. PAWS refers to a constellation of persistent protracted withdrawal symptoms that occur after acute alcohol withdrawal has resolved (typically 2–8 weeks post-cessation), lasting weeks to months. Symptoms include: anxiety, cognitive fog, sleep disturbances, mood instability, fatigue, reduced stress tolerance, and craving. Severity is associated with relapse risk. Used in addiction medicine and outpatient recovery contexts.
The EMBED (Emergency Department-initiated BuprenorphinE for opioid use Disorder) Score identifies patients presenting to the emergency department with opioid use disorder (OUD) who are most likely to be engaged in addiction treatment at 30 days following brief ED buprenorphine initiation + facilitated addiction treatment referral. Derived from the landmark Yale EMBED-1 trial (D'Onofrio et al. 2015). Provides prognostic information to guide shared decision-making about ED-initiated MOUD.
The Pediatric BIG Score combines base deficit (B), INR (I), and GCS (G) to predict mortality in pediatric trauma patients. The BIG score = base deficit + (2.5 × INR) + (15 − GCS). Higher BIG score predicts higher in-hospital mortality. The score was derived from a pediatric trauma database (Borgman et al.) and has been validated in multiple pediatric trauma populations as a simple, rapidly calculable mortality predictor requiring only 3 laboratory/clinical variables available at initial trauma assessment.
The Shock Index Pediatric Adjusted (SIPA) is an age-adjusted version of the adult Shock Index (heart rate ÷ systolic blood pressure) calibrated to normal pediatric vital sign ranges. Normal adult Shock Index (SI = HR/SBP) threshold is ≥ 0.8. Because children normally have higher heart rates and lower blood pressure than adults, the SIPA uses age-stratified cutoffs: SIPA ≥ 1.22 for ages 4–6 years, ≥ 1.0 for ages 7–12, and ≥ 0.9 for ages 13–16. An elevated SIPA predicts need for massive transfusion, blood product administration, and mortality in pediatric trauma.
The Danger Assessment (DA) is a validated 20-item clinical instrument developed by Dr. Jacquelyn Campbell to assess risk of lethal or near-lethal partner violence (femicide risk) in women experiencing intimate partner violence (IPV). Higher danger assessment score is associated with elevated risk of being killed by an intimate partner. The DA is widely used in emergency departments, shelters, criminal justice settings, and hospital-based violence advocacy programs to help women and clinicians understand lethality risk and make informed safety plans.
The TRIP (Thromboembolic Risk In Plaster) Score assesses VTE (venous thromboembolism — DVT/PE) risk in patients immobilized in cast or splint following lower extremity injury. Lower extremity immobilization (cast, splint, boot) is a well-established VTE risk factor. The TRIP Score stratifies patients into low, medium, or high risk categories to guide decision-making regarding VTE chemoprophylaxis during immobilization. Derived from a Dutch study (CAST study population).
The Revised Tokuhashi Score predicts estimated survival in patients with spinal metastasis to guide the extent of surgical intervention. A total score of 0–15 across 6 parameters (general condition KPS, number of extraspinal bone metastases, number of vertebral body metastases, internal organ metastases, primary tumor site, and spinal cord palsy) determines whether surgery should be palliative, limited, or excisional. Developed and revised by Tokuhashi et al. in 2005 from a Japanese cohort of 246 patients.
The Rib Fracture Score (also called RibScore) predicts complications requiring ICU-level care in patients with traumatic rib fractures. It incorporates number of rib fractures, bilateral fractures, flail chest, pulmonary contusion, and age to estimate risk of major pulmonary complications (pneumonia, respiratory failure requiring mechanical ventilation). Patients with high rib fracture scores benefit from early rib fixation (surgical stabilization), aggressive pain management, and respiratory physiotherapy.
The Bastion Classification system characterizes the severity of blast injuries to the lower extremity, developed from military trauma experience at Camp Bastion (UK military hospital, Helmand Province, Afghanistan). It classifies the anatomical zone of injury (I–IV, with higher zones indicating more proximal injury) and provides guidance on amputation planning and prosthetic potential. Zone I = foot/ankle, Zone II = tibial shaft, Zone III = knee/distal femur, Zone IV = femoral/above knee. May be combined with vascular injury assessment for limb salvage vs. amputation decision-making.
The Abbreviated Injury Scale (AIS) for Inhalation Injury / Lung Injury Score (LIS) characterizes pulmonary damage from smoke/thermal inhalation injury in burn patients. Inhalation injury is classified by injury level: upper airway (supraglottic), lower airway (subglottic/tracheobronchial), and parenchymal (pulmonary). Combined with patient age and burn surface area (TBSA), it determines intubation need, ventilator management strategy, and prognosis. The diagnosis of inhalation injury is made clinically and bronchoscopically.
The STUMBL (Sedation, Transfers, Urine output, Mechanical ventilation, Blood products, Lactate) Score is an early warning composite that integrates physiological parameters in trauma patients to predict early acute complications requiring ICU-level intervention. It extends traditional trauma triage by combining hemodynamic markers with resuscitation requirements, providing a rapid multivariable assessment in the first hours of trauma resuscitation. Applied to orthopedic trauma patients requiring early risk stratification for inpatient monitoring intensity.
The RibScore (Roberts et al., 2014) is a validated scoring system to predict pulmonary morbidity (pneumonia, respiratory failure, prolonged ventilation) from traumatic rib fractures. It incorporates 6 weighted variables: number of fractured ribs, bilateral rib fractures, flail segment, pulmonary contusion, hemothorax, and pneumothorax. The RibScore (distinct from generic rib fracture severity descriptions) provides a 0–10 point standardized score with validated outcome thresholds, and has been prospectively validated at multiple trauma centers.
The SCARF (Systematic Cardiovascular and Respiratory Fitness) Score is a perioperative assessment framework used in orthopedic surgery, trauma surgery, and high-risk elective orthopedic procedures to evaluate cardiorespiratory fitness and risk stratify patients before major orthopedic intervention. SCARF integrates functional exercise capacity (METs — metabolic equivalents), cardiac risk factors, pulmonary disease burden, and renal function to guide perioperative risk communication and optimization strategy.
The RESCUE-ICP (Risk Estimation Score for Cardiac Arrest after Cardiac Surgery or In-Hospital Cardiac Arrest with return of spontaneous circulation) predicts prognosis and likelihood of neurologically favorable survival after in-hospital cardiac arrest (IHCA) and successful resuscitation. It integrates pre-arrest characteristics, arrest features, and initial post-resuscitation physiology to estimate the probability of survival with good neurological outcome. Higher score = better predicted outcome.
The Sepsis-Induced Coagulopathy (SIC) Score is a bedside tool derived from the International Society on Thrombosis and Haemostasis (ISTH) that identifies patients with sepsis-induced coagulopathy — a precursor state to overt DIC (disseminated intravascular coagulation). SIC is diagnosed using: INR, platelet count, and total SOFA score. A SIC Score ≥ 4 identifies patients with sepsis who may benefit from anticoagulation therapy (particularly heparin). This score was the stratification tool used in the multicenter HESACOV/JMHW heparin studies.
The Cardiac Arrest Hospital Prognosis (CAHP) Score predicts the probability of poor 30-day neurological outcome (CPC 3–5) in comatose survivors of out-of-hospital cardiac arrest (OHCA) upon ICU admission. It incorporates 8 clinical variables available at hospital admission to provide early prognostication. CAHP score was derived and validated in two large French multicenter OHCA cohorts (n > 700). A CAHP score ≥ 150 predicts poor neurological outcome with high specificity.
The PRESET Score (PREdict Survival on ECMO Therapy) predicts in-hospital mortality in patients receiving venoarterial (VA) ECMO for refractory cardiogenic shock or cardiac arrest (ECPR — extracorporeal CPR). It was derived from a large multicenter French registry (ARCARDIA) of over 600 VA-ECMO patients and assigns points across 7 clinical variables at time of ECMO initiation. Higher PRESET score = higher predicted in-hospital mortality. Complements other ECMO selection tools (SAVE score for ECMO-on-arrival, SOFA, lactate clearance assessment).
The El-Ganzouri Risk Index (EGRI) is a validated pre-operative airway risk assessment score developed to predict difficult laryngoscopy and difficult intubation. It incorporates 7 independently weighted clinical variables: mouth opening, thyromental distance, Mallampati class, neck mobility, ability to prognath, weight, and history of difficult intubation. A score ≥ 4 identifies high risk for difficult laryngoscopy/intubation (sensitivity ~60%, specificity ~90%). EGRI was derived in a large prospective cohort of 10,000 patients.
The DKA Mortality Prediction Model (MPM) is a validated scoring system that estimates in-hospital mortality risk for patients admitted with diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar state (HHS). It was developed from a large retrospective U.S. cohort analysis using NIS (National Inpatient Sample) database and validated in a separate cohort. The score incorporates 8 clinical variables available at hospital admission, providing a quick stratification of DKA severity beyond standard mild/moderate/severe ADA classification.
The ROX Index (Respiratory OXygenation Index) predicts the risk of high-flow nasal oxygen (HFNO or HFNC — high-flow nasal cannula) therapy failure requiring escalation to endotracheal intubation in patients with acute hypoxemic respiratory failure (AHRF), primarily in pneumonia and COVID-19. Formula: ROX = (SpO₂ / FiO₂) / Respiratory Rate. A ROX Index ≥ 4.88 at 2, 6, or 12 hours into HFNO therapy predicts HFNO success (avoiding intubation). Originally derived and validated by Roca et al. in pneumonia patients, with extensive subsequent validation in COVID-19.
The Oxygenation Index (OI) is a standardized physiological measure of oxygenation efficiency in mechanically ventilated patients that accounts for both the degree of supplemental oxygen required AND the mean airway pressure (MAP) applied — unlike PaO₂/FiO₂ (P/F ratio) which only accounts for FiO₂. Formula: OI = (FiO₂ × Mean Airway Pressure × 100) / PaO₂. Higher OI = worse oxygenation for the level of ventilatory support. OI is the primary ARDS severity metric in the Pediatric Acute Lung Injury Consensus Conference (PALICC-2) criteria and is used to guide ECMO/inhaled nitric oxide decision-making in pediatric and neonatal intensive care.
The SET (Sepsis Early Triage) Score is a validated point-of-care sepsis risk stratification tool developed to identify emergency department (ED) patients with suspected infection who are at high risk for in-hospital mortality. It uses variables that are rapidly available in triage: vital signs, age, and a single laboratory value (lactate). SET Score was derived and validated in a large multicenter emergency setting as a simplified bedside alternative to SOFA/qSOFA that incorporates lactate as a key discriminator of tissue hypoperfusion.
The International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) Score is a validated prognostic model predicting 6-month unfavorable functional outcome (Glasgow Outcome Scale Extended — GOSE ≤ 4, which corresponds to severe disability, vegetative state, or death) after moderate-to-severe traumatic brain injury (TBI). Three IMPACT models exist: Core (4 variables), Extended (+ CT findings), and Lab (+ laboratory values). IMPACT was derived from 11 international TBI clinical trials and observational studies (n > 8,000) and is among the strongest TBI prognostic tools available.
The Modified Rankin Scale 9-Question (mRS-9Q) is a validated patient-reported outcome measure that assesses functional disability in patients with neurological conditions (particularly stroke, TBI, subarachnoid hemorrhage). The mRS-9Q consists of 9 yes/no questions about specific functional abilities that algorithmically map to an mRS score (0–6), providing a reliable surrogate for in-person structured interview administration. It allows remote or self-administered mRS assessment — important for clinical trials, telehealth follow-up, and mass casualty scenarios.
The Sudbury Vertigo Differentiation Tool is a bedside clinical decision aid developed to help emergency physicians differentiate central from peripheral causes of acute, spontaneous, persistent vertigo and dizziness. It combines three clinical examination tests — Head Impulse Test (HIT), Skew Deviation, and Nystagmus pattern — based on the validated HINTS examination, adapted with Sudbury modifications. The tool helps identify the minority of patients with dangerously central causes (stroke, cerebellar infarction, tumor) among the larger population presenting with benign peripheral vestibular disorders (vestibular neuritis, BPPV).
The ABC/2 Method is a validated bedside formula for rapid estimation of intracerebral hemorrhage (ICH) volume on CT scan without volumetric planimetry software. Formula: Volume = (A × B × C) / 2, where A = maximum hemorrhage diameter on hemorrhage slice, B = largest diameter perpendicular to A on same slice, C = number of CT slices with hemorrhage × slice thickness (mm). The ABC/2 method was validated against gold-standard planimetry (r = 0.98) and provides clinically meaningful volume estimation for ICH prognostication and management decisions.
A structured eligibility checklist for intravenous alteplase (IV tPA) administration in acute ischemic stroke (AIS) based on the 2019 AHA/ASA Updated Acute Ischemic Stroke Guidelines and 2023 AHA/ASA updates (tenecteplase considerations). Covers absolute and relative contraindications, patient selection for standard 3-hour and extended 4.5-hour windows, and current FDA-approved and off-label criteria. This checklist reflects the most current evidence-based eligibility criteria with annotation of which historically 'contraindications' are now relative vs. absolute based on post-marketing data.
The ASCOD Classification System is a validated etiological stroke classification framework that assigns individual probability grades (A = definite cause, B = uncertain cause, C = unlikely cause, 0 = absent, 9 = insufficient workup) to each of five potential stroke mechanisms: Atherosclerosis (A), Small vessel disease (S), Cardiac causes (C), Other causes (O), Dissection (D). Unlike binary classification systems (TOAST), ASCOD recognizes that multiple etiologies can simultaneously contribute to stroke etiology and allows capturing of incomplete or ongoing workup. It is used for research stratification and clinical decision-making on workup completeness.
FACE-DROPS is a clinical mnemonic and bedside assessment checklist for recognizing symptoms and signs of posterior circulation stroke (vertebrobasilar territory ischemia). Unlike anterior circulation strokes (facial droop, arm weakness, speech difficulty), posterior circulation strokes often present with subtle or atypical symptoms (vertigo, diplopia, dysphagia, ataxia) that are frequently misdiagnosed in the ED as benign peripheral BPPV or inner ear disease. FACE-DROPS stands for: Facial palsy, Ataxia, Confusion, Eyes (diplopia or nystagmus), Dysarthria, Reaching deficit, Occipital headache, Plus signs (Horner, hiccups, deafness), Swallowing difficulties.
The National Institutes of Health Stroke Scale (NIHSS) is the standardized, validated neurological assessment tool for quantifying stroke severity in acute ischemic and hemorrhagic stroke. This modified/abbreviated version captures the essential NIHSS items used in clinical practice for thrombolysis/thrombectomy selection, prognostication, and serial monitoring. Each item evaluates a specific neurological domain: consciousness, gaze, visual fields, facial palsy, arm/leg motor, ataxia, sensory, language, dysarthria, and inattention. NIHSS score correlates with stroke territory, infarct volume, and outcome.
The COVID-19 ICU Risk Calculator (CIRC) is an early prediction model developed from U.S. multicenter hospitalized COVID-19 patient data to identify patients at highest risk of requiring ICU-level care (mechanical ventilation, vasopressors, or ICU escalation) during hospitalization. CIRC uses 7 variables available at initial presentation: age, sex, BMI, SpO₂ on room air, comorbidity burden, C-reactive protein (CRP), and D-dimer. It was designed for early in-hospital triage to allocate ICU resources and identify patients who may benefit from early aggressive interventions.
The COVID-19 Hospitalization Early Escalation Score (CHOSEN) is a validated risk stratification tool developed to predict in-hospital deterioration requiring high-flow oxygen, mechanical ventilation, or death in COVID-19 inpatients within 48–72 hours of admission. It was derived from a Spanish multicenter COVID-19 cohort and incorporates initial clinical and laboratory parameters. Unlike general COVID severity scores, CHOSEN specifically targets EARLY INPATIENT deterioration — allowing proactive ICU transfer rather than reactive crash escalation.
The Brescia-COVID Respiratory Severity Scale (BCRSS) is a bedside clinical scoring tool developed at the COVID-19 unit in Brescia, Italy (one of the earliest heavily affected COVID-19 epicenters in 2020) to standardize respiratory monitoring and escalation decisions in hospitalized COVID-19 patients. The scale uses five evaluable clinical parameters: ability to lie supine, respiratory rate, SpO₂, confusion/agitation, and oxygen requirements — and generates 0–8 points that correspond to stepwise respiratory failure progression with specific management pathways at each level.
The Utah COVID-19 Severity Risk Score was developed by the University of Utah and Intermountain Healthcare to identify COVID-19 patients at highest risk for severe outcomes (ICU admission, mechanical ventilation, or in-hospital death) for prioritization of treatment resources and targeted monitoring. It was derived from a large electronic health record cohort during the first and second pandemic waves and incorporates comorbidities, demographic factors, and physiological measurements available at initial presentation.
The COVID-GRAM (COVID-19 Gram Risk Assessment Model) is a validated scoring tool derived from a large Chinese multicenter cohort (> 1,500 COVID-19 patients from 575 hospitals) to predict the probability of critical illness (composite: ICU admission, invasive mechanical ventilation, or death) in hospitalized COVID-19 patients. COVID-GRAM incorporates 10 variables identified through LASSO regression and multivariate logistic regression. A web-based calculator providing percentage risk outputs was made widely available during the early pandemic and gained international adoption.
The Veterans Affairs COVID-19 (VACO) Index is a mortality prediction model derived from the Veterans Health Administration (VA) electronic health record database of > 13,000 COVID-19-positive veterans to predict 30-day all-cause mortality following a positive SARS-CoV-2 test. The VACO Index uses age, sex, and Elixhauser comorbidity index to produce an individualized 30-day mortality probability. It was designed to be rapidly calculable from existing clinical data and has been validated in non-Veterans populations including NIH National Patient-Centered Clinical Research Network (PCORnet) multicenter data. VACO Index calibrates across demographic groups better than age-alone models.
The EPIPHANY Index (Estimates of Pulmonary Hypertension Index for Near-term prognosis in ANCHOR registry) is a simplified risk stratification score for patients with group 1 pulmonary arterial hypertension (PAH) to predict clinical worsening and mortality. It incorporates right heart catheterization hemodynamic parameters with clinical status to facilitate pulmonary hypertension management decisions and treatment escalation. The EPIPHANY approach simplifies the multi-dimensional European PAH risk assessment (COMPERA, REVEAL 2.0) while maintaining prognostic discrimination.
The Pulmonary Embolism Sub-massive At-Risk for Deterioration (PE-SARD) score is designed to identify intermediate-high risk (sub-massive) pulmonary embolism patients who are most likely to deteriorate or fail initial anticoagulation monotherapy — thereby identifying which patients may benefit from early reperfusion strategies (catheter-directed therapy, systemic thrombolysis, or surgical embolectomy) rather than expectant anticoagulation alone. The score addresses the clinical dilemma of managing the large 'gray zone' intermediate-risk PE patients where optimal management (anticoagulation vs. reperfusion vs. monitoring) is uncertain.
The Lung Injury Prediction Score (LIPS) is a validated clinical scoring tool developed to identify patients at high risk of developing Acute Respiratory Distress Syndrome (ARDS) — allowing early identification of at-risk patients for either preventive interventions or enrollment in prophylactic ARDS trials. LIPS was derived and externally validated in a large prospective multicenter US cohort (Lung Injury Prevention Study — LIPS) and incorporates predisposing conditions, high-risk diagnoses, and modifiable risk factors. Unlike ARDS Berlin Criteria (which diagnose established ARDS), LIPS predicts ARDS development BEFORE lung injury occurs.
The Respiratory Distress Observation Scale (RDOS) is a validated non-verbal clinical tool used by nurses and healthcare providers to assess and quantify respiratory distress in patients who are UNABLE to self-report dyspnea — including unconscious, endotracheally intubated, cognitively impaired, or obtunded patients. RDOS was developed and validated by Campbell et al. through systematic observation of behavioral and physiological indicators of respiratory distress in critical care and palliative care populations. RDOS provides 0–16 points and correlates with dyspnea intensity in those who can self-report, allowing care providers to infer and respond to respiratory distress when verbal report is impossible.
The Roth Score is a simple, validated bedside dyspnea quantification tool originally developed for COPD patients that measures the patient's ability to count aloud from 1 to 15 in a single exhalation using a stopwatch. The maximum count reached and the counting time strongly correlate with FEV₁, SpO₂, and COPD severity. The Roth Score provides an objective, reproducible, effort-independent measure of expiratory air reserve and dyspnea severity. Unlike the modified Medical Research Council (mMRC) dyspnea scale (activity-based), the Roth Score directly quantifies breathlessness at the moment of testing by challenging expiratory reserve.
Calculates the predicted normal peak expiratory flow (PEF) based on patient age, sex, and height using established Caucasian normative reference ranges (Wright and McKerrow 1959 / Nunn and Gregg 1989 values). Peak expiratory flow is the maximum airflow rate achieved during a forced exhalation from a position of full inspiration, measured in liters per minute (L/min). Predicted normal PEF is used as a reference to calculate the personal best or percentage of predicted PEF for asthma and COPD severity classification and monitoring. PEF < 50% predicted = severe acute exacerbation; < 25% predicted = life-threatening.
The SpO₂/FiO₂ (S/F) ratio is a validated non-invasive surrogate for the PaO₂/FiO₂ (P/F ratio) — the gold-standard oxygenation measurement requiring arterial blood gas (ABG). The S/F ratio uses pulse oximetry SpO₂ and the fraction of inspired oxygen (FiO₂) to estimate oxygenation status. Rice et al. (2007) validated the S/F ratio against P/F ratio in ARDS patients: S/F < 235 correlates with P/F < 200 (moderate ARDS); S/F < 315 correlates with P/F < 300 (mild ARDS). The ROX Index (SpO₂/FiO₂ ÷ RR) is derived from the S/F ratio and used specifically to predict HFNC success vs. failure.
The Pulmonary Index Score (PIS) is a validated clinical scoring tool to assess acute asthma exacerbation severity in adult patients presenting to the emergency department. It is a composite score combining five physiological parameters — respiratory rate, SpO₂, use of accessory muscles, air entry on auscultation, and expiratory wheezing pattern — to objectively quantify severity and guide treatment escalation decisions. PIS correlates closely with spirometric measurements (PEF, FEV₁) and has been validated in multiple asthma populations as a reliable tool for triage, monitoring response to therapy, and disposition decision-making (discharge vs. admission).
Calculates the Absolute Lymphocyte Count (ALC) from a complete blood count (CBC) differential. ALC = WBC × (% lymphocytes / 100). The ALC is a clinically critical derived value used in immunology, hematology, oncology, and infectious disease to quantify the total circulating lymphocyte population, assess immune competence, identify lymphopenia (ALC < 1.0 × 10⁹/L), lymphocytosis (ALC > 4.0 × 10⁹/L), and monitor immunosuppression or lymphoid malignancies.
Calculates the Neutrophil-to-Lymphocyte Ratio (NLR) from CBC differential — a widely validated systemic inflammation marker calculated as: NLR = Absolute Neutrophil Count ÷ Absolute Lymphocyte Count. NLR reflects the balance between the innate immune system (neutrophils — pro-inflammatory) and adaptive immune system (lymphocytes — anti-tumor, anti-viral). Elevated NLR indicates a state of systemic inflammation with relative immune suppression. NLR has been validated as a prognostic marker across oncology, cardiovascular disease, sepsis, COVID-19, and post-surgical outcomes.
The GARFIELD-AF (Global Anticoagulant Registry in the FIELD-Atrial Fibrillation) Risk Score is a validated prediction model derived from a large multinational real-world registry of > 50,000 patients with newly diagnosed non-valvular atrial fibrillation to simultaneously predict 1-year all-cause mortality, stroke/systemic embolism, and major bleeding. Unlike CHA₂DS₂-VASc which only predicts stroke risk, GARFIELD-AF provides competing risk estimates to aid in the individualized benefit-risk assessment of anticoagulation therapy — allowing comparison of ischemic stroke prevention benefit vs. bleeding risk for individual AF patients.
The SEX-SHOCK score is a clinical risk scoring tool developed to predict in-hospital mortality in patients presenting with cardiogenic shock — the most severe manifestation of acute heart failure. The acronym captures five core variables used for scoring. Cardiogenic shock (CS) carries 30–45% in-hospital mortality despite advances in revascularization and MCS (mechanical circulatory support). SEX-SHOCK was designed to rapidly risk-stratify CS patients for intensity of care, MCS candidacy, and early transfer to advanced cardiology centers with full MCS capabilities (ECMO, Impella, IABP).
The PRIMACY (PRImary vs. secondary Myocardial infarCtion aetiologY) score is a validated clinical prediction tool designed to differentiate Type 1 MI (spontaneous plaque rupture/erosion — coronary stenting or thrombolysis indicated) from Type 2 MI (myocardial oxygen supply-demand mismatch from non-atherosclerotic causes — treat the underlying trigger rather than the coronary artery). This distinction is clinically critical because the management pathways differ fundamentally, yet presentation can be identical. PRIMACY uses six variables to generate a probability of primary (Type 1) MI, allowing appropriate triage to catheterization lab vs. medical management of the precipitating condition.
The Emergency Heart Failure Mortality Risk Grade (EHMRG) is a validated 7-day mortality prediction score developed from a large Ontario, Canada administrative healthcare database of > 12,000 emergency department acute decompensated heart failure (ADHF) presentations. EHMRG uses 11 readily available clinical and laboratory variables to generate a risk level (very low to high) associated with 7-day mortality probabilities, enabling evidence-based disposition decisions: safe discharge from ED with aggressive outpatient follow-up (very low risk) vs. hospital admission vs. ICU admission (high risk). A prospective implementation study (EHMRG30-ST) confirmed its discriminatory power.
The READMITS score (REnal function, Diagnosis, Male sex, Admission Insulin Treatment, Systolic blood pressure, and Type of admission) is a validated clinical prediction tool developed to identify heart failure patients at high risk for 30-day hospital readmission after an index heart failure hospitalization. It was derived and validated from a large multicenter heart failure registry to help guide discharge planning, post-discharge follow-up intensity, and resource allocation to reduce the substantial 30-day readmission rate following heart failure hospitalization (approximately 25–30% in the U.S. — the leading cause of preventable hospital readmission under the CMS Hospital Readmissions Reduction Program).
The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a standardized consensus definition to identify percutaneous coronary intervention (PCI) patients at high risk for major bleeding complications on dual antiplatelet therapy (DAPT). Developed by a multinational consortium of cardiologists, the ARC-HBR definition includes 20 criteria (major and minor) that classify PCI patients as 'High Bleeding Risk' (HBR) — defined as BARC 3 or 5 bleeding risk ≥ 4% at 1 year OR intracranial hemorrhage rate ≥ 1% at 1 year. HBR identification allows tailoring of DAPT duration (shortened from standard 12 months), antiplatelet selection (clopidogrel over ticagrelor/prasugrel), and stent selection (newer-generation stents with shorter DAPT requirements).
The Wound, Ischemia, and foot Infection (WIfI) classification system is a validated, evidence-based staging framework developed by the Society for Vascular Surgery (SVS) to standardize risk assessment for patients with lower extremity peripheral arterial disease (PAD) with threatened limb status. WIfI replaces older classifications (Fontaine, Rutherford) for critical limb ischemia (CLI) by incorporating three independent determinants of amputation risk: (1) Wound severity, (2) Ischemia degree, and (3) foot Infection presence/severity. Combined WIfI staging (0–4) predicts 1-year amputation risk and benefit from revascularization, enabling more accurate limb salvage planning.
The PASCAL Classification (Prognostic Assessments Scale for CLinical evidence-based risk stratification) is a simplified, validated 3-tier risk stratification system for pulmonary arterial hypertension (PAH) developed by the European Society of Cardiology/European Respiratory Society (ESC/ERS) from large multicenter PAH registries. PASCAL classifies patients with established PAH into Low (L), Intermediate-Low (IL), Intermediate-High (IH), and High (H) risk categories based on: functional class, 6-minute walk test, BNP/NT-proBNP, echocardiographic right heart parameters, and right heart catheterization hemodynamics. PASCAL predicts 1-year mortality probability for each risk tier and guides treatment escalation decisions.
The Fick Principle is the gold-standard method for measuring cardiac output (CO) during right heart catheterization. The Fick equation calculates CO based on the relationship between whole-body oxygen consumption (VO₂) and the arteriovenous oxygen content difference: CO = VO₂ / (CaO₂ − CvO₂). The Fick principle is particularly accurate in patients with low cardiac output states (< 3.5 L/min) where thermodilution methods (Swan-Ganz catheter) are less reliable due to variability with low-flow states, tricuspid regurgitation, or intracardiac shunts. The Cardiac Index (CI = CO/BSA) normalizes for body size and is the key prognostic hemodynamic parameter in heart failure, cardiogenic shock, and pulmonary hypertension.
Cardiac Power Output (CPO) is a single hemodynamic parameter that integrates both pressure and flow components of cardiac performance: CPO = (Mean Arterial Pressure × Cardiac Output) / 451 (in Watts). CPO is the strongest hemodynamic predictor of in-hospital mortality in cardiogenic shock and acute myocardial infarction complicated by cardiogenic shock. Derived from right heart catheterization data, CPO < 0.6 W identifies patients at highest mortality risk and is a threshold commonly used to guide mechanical circulatory support (MCS) escalation decisions. The cardiac power index (CPI = CPO / BSA) normalizes for body size.
The TIMI Risk Index (TRI) is a simple bedside calculation that provides a rapid estimate of 30-day mortality risk in patients presenting with ST-elevation myocardial infarction (STEMI). Derived from the large TIMI 9 and InTIME-II clinical trials, TRI uses three universally available parameters at presentation: heart rate, systolic blood pressure, and age. The formula TRI = (Heart Rate × [Age / 10]²) / Systolic Blood Pressure produces a score that stratifies patients into risk deciles with 30-day mortality ranging from < 1% (lowest decile) to > 35% (highest decile). TRI facilitates rapid risk communication and guides intensity of initial STEMI management.
The ACEF II Score (Age, Creatinine, Ejection Fraction) is a simplified preoperative risk stratification tool for adult patients undergoing cardiac surgery, designed to predict 30-day/in-hospital operative mortality. The original ACEF score formula (Age/EF + 1 if Cr > 2 mg/dL) was updated to ACEF II by incorporating an emerging risk factor (history of cardiac surgery) and refining continuous creatinine integration. ACEF II is validated against EuroSCORE II and STS Score in multiple European cohorts, demonstrating comparable mortality discrimination for common cardiac surgeries (CABG, valve replacement/repair, combined procedures) with the advantage of rapid 3-variable bedside calculation.
The HCM Risk-SCD is the 2014 European Society of Cardiology (ESC) validated prediction model for estimating 5-year risk of sudden cardiac death (SCD) in adults with hypertrophic cardiomyopathy (HCM). The model integrates 7 clinical and imaging predictors into a continuous mathematical equation that generates a 5-year SCD probability, enabling evidence-based ICD implantation decisions. Unlike older binary 'minor/major risk factor' classification systems, HCM Risk-SCD provides a continuous probability estimate, capturing more nuanced risk gradients. The model was derived from the HCM European Registry (3675 patients) and validated externally, and its use is endorsed in 2014 ESC and 2020 ACC/AHA HCM guidelines.
The Framingham Coronary Heart Disease (CHD) Risk Score is the original landmark 10-year cardiovascular risk prediction model derived from the Framingham Heart Study — a prospective longitudinal cohort study of cardiovascular disease since 1948. The sex-specific Framingham CHD Risk Score (D'Agostino 2008 update) integrates traditional cardiovascular risk factors (age, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure treatment status, diabetes, and smoking status) to estimate 10-year probability of a first cardiovascular event (MI, coronary death, angina, coronary insufficiency, stroke, TIA, or peripheral arterial disease). The Framingham CHD score laid the conceptual foundation for all subsequent global CV risk prediction models (ASCVD Pooled Cohort Equations, SCORE, QRISK).
The CHADS-65 algorithm is a simplified 2016 Canadian Cardiovascular Society (CCS) AF guideline recommendation for atrial fibrillation (AF) anticoagulation decision-making in adults. It replaces the older CHA₂DS₂-VASc scoring system with a streamlined, binary decision framework: (1) Is the patient ≥ 65 years AND/OR does the patient have any ONE of C-H-A-D-S risk factors (Congestive Heart Failure, Hypertension, Age ≥ 75, Diabetes, Stroke/TIA/thromboembolism)? If either criterion is met → anticoagulate. The simplification was designed to improve clinical implementation and reduce systematic under-anticoagulation, which remains problematically high in North American clinical practice.
The PREVENT (Predicting Risk of CVD Events) equations are the 2023 American Heart Association replacement for the 2013 Pooled Cohort Equations (PCE) for 10-year primary cardiovascular risk prediction in adults. PREVENT was derived from 6.6 million U.S. adults in diverse contemporary cohorts. Key improvements over PCE: (1) Broader outcome composite (total CVD = atherosclerotic CVD + heart failure + atrial fibrillation; plus separate 10-year ASCVD equation); (2) Incorporation of eGFR and metabolic syndrome syndrome variables; (3) Better calibration in Black, Hispanic, and non-White populations; (4) No longer sex-specific; (5) Optional incorporation of urine ACR for further refinement.
The Newsom Score is a validated clinical decision tool developed to predict which post-cardiac arrest patients without ST-elevation on post-ROSC ECG harbor an acute coronary occlusion requiring emergency coronary angiography and intervention. In patients resuscitated from out-of-hospital cardiac arrest (OHCA) without ST-elevation, the rate of acute culprit coronary occlusion is 25–35% — yet the TOMAHAWK and COACT trials showed that immediate coronary angiography does not improve 30-day mortality vs. delayed angiography in unselected NSTE-arrest patients. The Newsom Score identifies the subset of NSTE-arrest patients most likely to have an acute coronary lesion, enabling targeted emergent catheterization versus cooling and deferred angiography.
The Blood Urea Nitrogen-to-Creatinine (BUN/Cr) ratio is a simple calculated biomarker used to differentiate prerenal azotemia from intrinsic renal causes of acute kidney injury (AKI), and to estimate the etiology of elevated creatinine. Normal BUN/Cr ratio: 10–15. An elevated ratio (> 20) suggests prerenal azotemia (dehydration, heart failure, GI bleeding, sepsis-related hypoperfusion). A low ratio (< 10) suggests intrinsic renal causes, including acute tubular necrosis (ATN), glomerulonephritis, or SIADH. BUN/Cr interpretation is also clinically relevant for upper GI bleeding detection (protein load from blood digestion) and for identifying hypercatabolic states.
The 2023 Emergency Medicine Evaluation and Management (E/M) coding framework reflects the American Medical Association (AMA) and Centers for Medicare and Medicaid Services (CMS) updates to ED/emergency department E/M code levels (99281–99285). The 2023 revisions aligned ED coding with the office visit E/M changes (which eliminated history and physical exam as primary determinants), focusing instead on Medical Decision Making (MDM) complexity as the dominant determinant of E/M level. For ED visits, all three components — history, physical exam, and MDM — are still considered, but MDM complexity drives most encounters. Accurate E/M coding is a legal and compliance requirement under federal anti-kickback statutes and the False Claims Act.
The Relative Fat Mass (RFM) is a validated body composition index developed by Woolcott and Bergman (2018) as an accurate predictor of whole-body fat percentage, outperforming traditional body mass index (BMI) in estimating adiposity. RFM is calculated from waist circumference and height measurements without requiring expensive dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance: RFM = 64 – (20 × Height/Waist) [men] or RFM = 76 – (20 × Height/Waist) [women]. Unlike BMI (which does not distinguish fat from lean body mass), RFM correlates strongly with DXA-measured body fat percentage (r² = 0.73 in men, 0.82 in women) and predicts visceral adiposity and cardiometabolic risk more accurately.
The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is a validated mathematical model that uses fasting glucose and fasting insulin concentrations to estimate whole-body insulin resistance (IR) and beta-cell function. Developed by Matthews and colleagues at Oxford in 1985, HOMA-IR is the most widely used clinical research tool for quantifying insulin resistance. Formula: HOMA-IR = (Fasting Glucose [mg/dL] × Fasting Insulin [μIU/mL]) / 405. HOMA-IR correlates strongly with the hyperinsulinemic-euglycemic clamp (gold standard for IR measurement) and with visceral adiposity, non-alcoholic fatty liver disease (NAFLD/MASLD), PCOS, metabolic syndrome, and type 2 diabetes risk.
The Estimated Average Glucose (eAG) from HbA1c is a validated conversion that translates HbA1c percentage into a real-world average blood glucose value in mg/dL or mmol/L that patients can relate to their daily glucometer readings. The formula is derived from the ADAG (A1c-Derived Average Glucose) study, which enrolled 507 subjects with T1DM, T2DM, and no diabetes and correlated continuous glucose monitoring (CGM) readings with simultaneous HbA1c measurements: eAG (mg/dL) = (28.7 × HbA1c) − 46.7. This conversion helps bridge the gap between laboratory HbA1c values and the daily glucose experience of patients with diabetes, supporting patient education and glycemic management.
The Pack-Years calculator quantifies cumulative tobacco smoking exposure in a standardized unit: one pack-year equals smoking one pack (20 cigarettes) per day for one year. Formula: Pack-Years = (Packs smoked per day) × (Years smoked) = (Cigarettes per day / 20) × Years smoked. Pack-year history is a critical clinical parameter used for: lung cancer screening eligibility (low-dose CT; USPSTF 2021 criteria require ≥ 20 pack-years), COPD severity assessment and spirometric prediction, perioperative risk stratification, insurance mortality risk scoring, and epidemiologic research. Pack-years provide a single quantitative summary of tobacco exposure that captures both duration and intensity of smoking.
The HOSPITAL Score is a validated 7-variable clinical prediction model for estimating the probability of 30-day potentially preventable hospital readmission after any acute hospitalization. Developed by Donzé et al. at the Brigham and Women's Hospital and validated in multiple international cohorts, the HOSPITAL Score assigns integer points to: low sodium at discharge, oncology admission, low hemoglobin, procedure during hospitalization, index admission type (internal medicine), number of admissions in prior year, and length of stay. It was specifically designed to identify patients at high readmission risk who may benefit from intensive post-discharge transitional care interventions. The score is incorporated in several electronic health records (EHR) readmission prediction systems.
The DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) criteria for Major Depressive Disorder (MDD) provide the standardized clinical diagnostic framework for this highly prevalent psychiatric condition. MDD is diagnosed when five or more specific symptoms are present during the same 2-week period, representing a change from previous functioning, with at least one symptom being either (1) depressed mood or (2) loss of interest/pleasure. These nine criteria (SIGECAPS mnemonic: Sleep, Interest, Guilt, Energy, Concentration, Appetite, Psychomotor, Suicidality) must cause significant social or occupational impairment and not be attributable to substances, medical conditions, or other psychiatric disorders.
The Edmonton Symptom Assessment System — Revised (ESAS-r) is a validated, patient-reported outcome measure widely used in palliative care and oncology settings to assess the severity of nine common symptoms experienced by patients with advanced illness: pain, tiredness, drowsiness, nausea, appetite, depression, anxiety, wellbeing, and shortness of breath. Each symptom is scored by the patient on a numeric rating scale (NRS) from 0 (none) to 10 (worst possible). ESAS-r is recommended by the Canadian Association of Palliative Care (CAPC), the American Academy of Hospice and Palliative Medicine (AAHPM), and is integrated into provincial cancer care programs across Canada. Serial ESAS-r assessments track symptom trajectories over disease course.
The Wound Closure Classification system categorizes wounds and surgical incisions into standardized closure intent categories: Primary intention (immediate closure), Secondary intention (allow to heal without closure), Delayed primary closure (DPC, tertiary), and Open with prophylactic grafting. This classification framework, used in emergency medicine, surgery, and wound care, determines the optimal closure technique based on: time since injury, degree of contamination, tissue loss, vascular supply, and infection risk factors. Proper wound classification ensures appropriate healing strategy selection and reduces post-procedure infection rates, dehiscence, and poor cosmetic outcomes.
The Hypoglycemia Risk Score is a clinical assessment tool designed to quantify the risk of severe and recurrent iatrogenic hypoglycemia in patients with diabetes mellitus, particularly those on insulin or secretagogue therapy. Severe hypoglycemia (blood glucose < 54 mg/dL or requiring third-party assistance) is the most dangerous acute complication of diabetes treatment, associated with significant morbidity including cardiac arrhythmias, falls, seizures, and excess mortality (ACCORD trial). This scoring tool integrates established clinical risk factors for hypoglycemia to guide glycemic target modification, treatment regimen adjustment, glucose monitoring intensity, and patient education intensity.
The ACEP 2024 Clinical Policy on evaluation and management of adult patients presenting to the emergency department with blunt abdominal trauma provides evidence-based recommendations for imaging strategy, observation protocols, and operative decision-making. This clinical decision tool guides ED clinicians through key recommendations regarding CT abdomen/pelvis utilization, seat belt sign significance, diagnostic peritoneal lavage indications, and serial examination protocols for the stable blunt trauma patient.
The ACEP 2025 Clinical Policy on evaluation and management of patients presenting to the emergency department with elevated blood pressure (asymptomatic hypertension, hypertensive urgency, and hypertensive emergency/crisis) provides evidence-based guidance on: evaluation for end-organ damage, treatment thresholds, medication selection, and safe disposition. This policy distinguishes hypertensive urgency (severely elevated BP without end-organ damage) from hypertensive emergency (severely elevated BP WITH acute end-organ damage — brain, heart, kidney, aorta, eye), guiding appropriate ED treatment intensity and disposition.
The ACEP 2024 Clinical Policy on the use of intravenous thrombolytics (IV alteplase/tPA and tenecteplase) for acute ischemic stroke synthesizes evidence-based recommendations for patient selection, contraindications, dosing, and time windows. This decision tool guides emergency physicians through eligibility assessment and risk-benefit communication for IV thrombolysis in the acute stroke patient — the most time-critical intervention in emergency medicine ('Time is Brain': approximately 1.9 million neurons lost per minute of untreated ischemic stroke). Tenecteplase (TNK) is included as an evidence-based alternative to alteplase in most patients.
The ACEP Clinical Policy on evaluation of adult emergency department patients with transient ischemic attack (TIA) and minor stroke addresses critical early management decisions including risk stratification for stroke, neuroimaging selection, antiplatelet initiation, and safe hospitalization vs. expedited outpatient management. TIA (formerly 'mini-stroke') is defined by the 2009 AHA/ASA tissue-based definition as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia WITHOUT acute infarction on MRI. Stroke risk post-TIA peaks within 48 hours of event — the ED encounter is the critical opportunity for secondary prevention.
The ACEP 2019 Clinical Policy on evaluation and management of adult patients with acute headache in the emergency department provides evidence-based recommendations for: identifying dangerous secondary causes of headache (subarachnoid hemorrhage, meningitis, venous thrombosis, hypertensive emergency), appropriate neuroimaging utilization, and parenteral treatment protocols for acute migraine and headache syndromes. Headache accounts for approximately 3–5% of all ED visits annually (~2–3 million visits). Less than 5% of all ED headache presentations represent life-threatening etiologies, yet distinguishing dangerous from benign headache remains the critical ED clinical challenge.
The ACEP 2024 Clinical Policy on evaluation and management of adult ED patients with first unprovoked seizure provides evidence-based guidance on: risk stratification for seizure recurrence, neuroimaging and EEG indications, antiepileptic drug (AED) initiation decision-making, and safe disposition. A separate component addresses status epilepticus (SE) management — seizure activity ≥ 5 minutes (ILAE 2015 operational definition) or two seizures without return to baseline — which represents a medical and neurological emergency requiring rapid benzodiazepine administration and escalating treatment if initial therapy fails.
The ACEP 2020 Clinical Policy on prescribing opioid analgesics in the emergency department provides evidence-based guidance on appropriate use of opioids for acute pain management, risk mitigation strategies, alternatives to opioids (multimodal analgesia), naloxone co-prescription, and ED-based opioid use disorder (OUD) treatment integration. The opioid crisis — responsible for > 80,000 overdose deaths per year in North America (2022) — demands that ED prescribers make deliberate, evidence-driven opioid prescribing decisions while not under-treating legitimate acute pain.
The ACEP 2023 Clinical Policy on management of acute agitation in the emergency department provides evidence-based, safety-focused guidance on pharmacological and non-pharmacological interventions for acute agitation. Acute undifferentiated agitation in the ED requires rapid assessment, de-escalation attempts, and — when chemical sedation is needed — evidence-based medication selection minimizing respiratory complications. The policy covers: droperidol, haloperidol, ketamine, benzodiazepines, and the emerging role of dexmedetomidine for acute agitation management across different etiologies (toxicological, psychiatric, medical, alcohol).
The ACEP 2022 Clinical Policy on evaluation and management of acute decompensated heart failure (ADHF) in the emergency department synthesizes evidence for initial diagnosis, risk stratification, and treatment decisions — with emphasis on high-dose IV diuresis, vasodilator therapy, non-invasive ventilation, and identifying patients who require emergent mechanical support versus those safe for ED-based treatment and early discharge. Heart failure is the leading cause of hospitalization in adults over 65, and the ED encounter is critical for reversing acute fluid overload and determining safe disposition.
The ACEP 2014 Clinical Policy on evaluation and management of suspected thoracic aortic dissection in the emergency department provides evidence-based guidance for recognizing this time-critical emergency, risk stratification using the Aortic Dissection Detection Risk Score (ADD-RS), appropriate imaging strategies, and initial medical management. Thoracic aortic dissection (TAD) represents one of emergency medicine's most lethal diagnostic traps — with mortality increasing 1–2% per hour from Type A (ascending) dissection and devastating consequences from missed diagnosis.
The ACEP 2020 Clinical Policy on evaluation and management of community-acquired pneumonia (CAP) in adult emergency department patients provides evidence-based guidance on: radiographic diagnostic strategy, risk stratification for safe discharge vs. admission (PSI/PORT score, CURB-65), antibiotic selection based on severity and resistance risk, and post-discharge follow-up. CAP is the most common infectious cause of death in the US and the leading cause of sepsis in the ED, with significant variability in practice regarding antibiotic selection, route, and admission decisions.
The ACEP 2025 Clinical Policy on evaluation and management of carbon monoxide (CO) poisoning in adult ED patients provides evidence-based guidance on diagnosis, carboxyhemoglobin (COHb) threshold interpretation, neurological injury prediction, indications for hyperbaric oxygen therapy (HBOT), and mandatory safety actions (environmental investigation). CO poisoning affects ~50,000 Americans per year requiring ED visits, with approximately 430 unintentional CO poisoning deaths annually. CO is the 'silent killer' — odorless, colorless, and capable of producing COHb elevations without warning device activation in mild exposures.
The ACEP 2023 Clinical Policy on evaluation and management of adult ED patients with suspected acute appendicitis provides evidence-based guidance on: clinical risk stratification using validated scoring systems (Alvarado score, Adult Appendicitis Score, AIR Score), imaging strategy including ultrasound, CT, and MRI utilization, antibiotic treatment for uncomplicated appendicitis, and appendectomy vs. non-operative management (NOM). Acute appendicitis remains the most common acute surgical abdominal emergency (~300,000 appendectomies annually in North America), but evidence supports that a subset of uncomplicated appendicitis cases can be managed with antibiotics alone.
The ACEP Clinical Policy on evaluation of febrile infants (age 29 days to 3 months) in the emergency department provides evidence-based guidance for risk stratification of serious bacterial infection (SBI) — bacteremia, meningitis, urinary tract infection, pneumonia, enteritis. Febrile infants in this age group have immature humoral and cellular immunity, unreliable clinical examination, and potentially masked presentations of life-threatening infections. Multiple validated clinical decision rules (Rochester Criteria, Philadelphia Criteria, Boston Criteria, and the newer Step-by-Step rule and PECARN Febrile Infant rule) are available to guide lumbar puncture, blood culture, and hospitalization decisions.
The ACEP 2023 Clinical Policy on evaluation and management of adult patients with mild traumatic brain injury (mTBI) / concussion in the emergency department synthesizes evidence for: CT head imaging decision rules (Canadian CT Head Rule, NEXUS II, New Orleans Criteria), intracranial hemorrhage risk stratification in anticoagulated patients, observation vs. discharge decision-making, post-concussion follow-up, and specific populations (anticoagulated patients, elderly). Concussion (mTBI) represents approximately 70–90% of all TBI presentations to EDs and is the most common traumatic brain injury encountered in emergency practice.